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ABSTRACT 
Compliance with Protease Inhibitors therapy is a very significant problem because non-
compliant patients may develop resistance. The factors associated with compliance 
were examined in an HIV infected population (n=73) who were currently being 
prescribed a Protease Inhibitor. Data on demographics, clinical characteristics, mood 
status and coping were obtained. Compliance was measured by the ''temptation to skip 
Protease Inhibitor scale" and "number of doses missed in the past three months". 
Multiple regression was used to examine three sets of predictors variables. Amongst 
the demographic predictors, number of people in household was significantly 
associated (p<0.01) with the dependent variable "Temptation to skip Protease 
Inhibitor" while gender was significantly associated with the dependent variable 
"number of doses missed in the past three months". The other demographic variables 
showed little association with compliance. 
Amongst the clinical predictors, pain interfering with work in the past four weeks 
significantly predicted the temptation to skip Protease Inhibitor therapy while none of 
the clinical predictors were associated with the number of doses missed in the past 3 
months. 
General mental health and behavioral escape avoidance were the mood and coping 
variables that showed significant associations with the temptation to skip Protease 
Inhibitors. None of these predicted the number of doses missed in the past three 
months. 
Finally a multivariate model was developed which investigated factors which were 
most highly associated with medication compliance. General mental health and number 
11 
of people in household appeared to be the most highly associated factors. These 
results suggested that patients should be treated for psychological distress and their 
families should be informed about the importance of social support to reduce the 
impact of this problem. 
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( INRODUCTION 
A. Importance of Compliance with Protease Inhibitors 
Advances in HIV pathogenesis and viral dynamics, and availability of viral 
load assays and potent antiretroviral drug regimens had provided new opportunities to 
treat patients with HIV disease. Combined aggressive antiretroviral therapy has 
enormous potential to delay disease progression and death (Friedland G, JAMA, 
1997). But this new combination regimen is v,ery demanding and requires a very strict 
dosing schedule. It was found that ·resistance developed rapidly when doses were 
missed or taken in inadequate amounts. Because cross resistance could occur among 
the Protease Inhibitors, patients whose HIV developed resistance to one Protease 
Inhibitors had limited antiretroviral therapy options in the future (Geletko S., 
Khurram Z., Medicine and health Rhode Island, 1998) The prospect of resistance not 
only made individual patients more vulnerable, it also raised the specter of a public 
health threat that could neutralize recent therapeutic advances. This resulted in the 
issue of compliance gaining considerable interest among health care providers. In 
theory, if compliance is complete(100%) with potent combination therapy, viral 
replication will most likely be halted and resistance mutant are unlikely. However, in 
patients who intermittently or irregularly take drugs, the likelihood of selection of 
mutants that are resistant to drugs increase, a consequence of both continuing viral 
replication and selective ·automicrobial pressure (Friedland G., JAMA, 1998). 
Enormous amount of studies with HIV disease and other chronic condition 
have shown that sociodemographic variables rarely predict compliance. The reason 
for noncompliance seems to be multifaceted in nature including psychological and 
emotional factors. 
This study will explore the factors associated with compliance and further 
investigate which of these factors are most highly associated with patient compliance. 
B. Determinants of Compliance 
Over roughly the past two decades, there haye been more than 700 studies, about 35 
. 
each year, that have examined variables that could be demonstrated as predictive of 
adherence to various medical regimen (Morisky DE; Green L W; Levine DM; Med 
Care, 1986). 
I . Patient Characteristics 
Education, income, age and other basic sociodemographic markers have shown some 
correlation with compliance but not consistently and not at significant levels. Haynes 
(1976) noted that while some studies showed an association between noncompliance 
and lower socioeconomic status, poor education and older age, the majority showed 
no such association. There is also no association found between noncompliance and 
age or sex. In terms of patient characteristics, social support is probably the most 
important factor. (Friedland G.,1998) 
Thus compliance is not related to income, social class, occupation or educational 
background and it cannot be accurately predicted by physicians (Greenberg 
R,Clinical Therapeutics, 1984). 
2 
II . Clinical Characteristics 
a. Diagnoses: Haynes (1979) has reviewed the literature critically and has 
commented that there are few obvious associations between disease features and 
compliance. 
b. Severity of Illness: It seems reasonable to expect more severely ill patients to be 
more compliant with treatment than less severely ill patient (Evans L, Spelman M, 
Drugs, 1983). Davis (1966) found on the contrary. He found that those with 
severe ailments were more likely to fail thaii those with less severe disorders. 
However he noted that it is difficult to be sure whether the noncompliance affects 
the severity of the condition and vice versa He also found that greater the effect 
of the illness on performing daily activities, the less likely the patient was to 
follow the doctors advice. 
The one association between illness and noncompliance that is consistently 
reported is that when patients get better from an illness they are less likely to 
comply with treatment (Heinzelman,1962; Johnson,1973; Prien & Caffey,1977; 
Rickels et al, 1968). 
III. Psychological and emotional characteristics: 
These play a greater role in determining compliance than demographic factors. 
a) Coping: The experience of being diagnosed with HIV infection or AIDS IS 
extremely stressful. Coping is viewed as a response to perceived stress and it has been 
defined as the "constantly changing cognitive and behavioral effort to manage 
specific external and/or internal demands that are appraised as taxing or exceeding the 
resources of the person 
3 
( (Lazarus & Folkman, 1984, p 141). 
In the literature there are a lot of coping strategies identified but there was little 
consensus regarding which coping strategies are effective in dealing with stress. 
Although researchers have found that coping strategies relate to psychological & 
physical illness, which coping mechanism is most effective may depend on the nature 
of the situation. (Baum, Fleming & Singer,1983; Billing & Moos,1981; Felton & 
Revenson,1984; Harburg, Blakelock, '& i_Reoper,1979; Holahan & Moos, 1986; 
Kobasa 1982; Mitchell, cronkite & Moos, 1983; Piarlin & Schooler,1978). 
The specific fears of persons with HIV infection and AIDS include abandonment, 
pain, death, and the exposure of their homosexuality, bisexuality, drug use, 
prostitution, or unsafe sexual activity. The uncertainty of the outcome of the infection 
can lead to anxiety. The reaction of others to the patients' diagnosis constitute a 
significant concern (Ross & Rosser, 1988). In addition, individuals may not be able to 
conceal their illness from significant others if their symptoms are sufficiently severe. 
They may need to take time off from work or stop working altogether. Such changes 
may lead to cessation of employer-paid health insurance benefits, social supports, 
contact with acquaintances, and income. The stresses of having to give up work are 
considerable, often leading to depression and lack of self-esteem (Ross & Rosser, 
1988). 
The role of moderating variables in the relationship between stressful events and 
.. 
adaptational outcomes has gained considerable attention (Johnson,J.H., Sarason, LG., 
Stress and Anxiety, 1979). Extensive research in this area has demonstrated that 
coping is a major moderating variable in the stress-illness relationship (Billing & 
4 
Moos, 1984; Coyne, Aldwin & Lazarus, 1981; Lazarus, Folkman, Green & 
DeLongis, 1986). Five patterns of coping were identified by a study done on cancer 
patients (Denkel-Schetter C., Feinstein L., Taylor S., Falke R., 1992). "seeking or 
using social support" describes efforts to seek informational support, tangible support, 
and emotional support. "Focusing on the positive" describes efforts to create positive 
meaning by focusing on personal growth. "Distancing" describes cognitive efforts to 
detach oneself and to minimize the sigllificapce of the situation. "Cognitive escape-
avoidance" and "Behavioral escape-avoidance ; describes wishful thinking and 
behavioral efforts to escape or avoid the problem. 
b.) Mood Status: A level of anxiety either too low or too great may well be related to 
noncompliance(Evans L., Spelman M., Drugs, 1983). Studies in IDV suggest that 
psychosocial stress associated with the illness adversely affects the quality of life 
in IDV patients (Fawzy et al., 1989; Holland et al,1985; Solomon et al,1989). 
Many of the cognitive, psychological, social, and environmental factors that 
determine the individual's psychosocial well-being and quality of life also have 
an impact on compliance. 
The SF-36 derived from the work of the Rand Corporation of Santa Monica during 
1970 is a generic indicator of health status. It was designed tobe applicable to a wide 
range of types and severities of condition. These were useful for monitoring patients 
with multiple conditions, for comparing the health status of patients with different 
conditions, and for comparing patients to the general population. Perceived well-
being is subjective and cannot be completely inferred from behavior; hence the SF-36 
5 
included questions on feeling states. (Mc Dowell I. , Newell C., Measuring health, 2"d 
edition, p 446). 
C. Assessment of Compliance 
There is no ideal method to assess drug compliance. Four methods are 
commonly used to measure compliance: self-reported (questionnaire/interview/diary), 
pill count, drug assay, and electronic monitoring. 
Self Reported Questionnaire: Is cominonly used as it is relatively simple and 
inexpensive method. Sometimes it inay be the orily- method available. Studies have 
indicated that only 25-50% of non compliant patients can be identified by interview. 
It was found that there was a significant correlation between the proportion of missed 
doses according to interview and objective method (Roth HP, Caron HS, Clinical 
Pharmacol Ther, 1978).Though this method may not be accurate there may be reason 
to believe it is useful because patients reporting non compliance are usually at least as 
non compliant as indicated by interview (Norell SE, Soc Sci Med, 1981 ). There also 
is evidence that patients reporting non compliance are more likely to respond to 
compliance-improving strategies than other non compliant patients (Haynes RB, 
Sackett DL, Gibson ES, et al Lancet,1976) 
Pill Count: The method of counting tablets to determine patient medication behaviour 
was described in 1936 by Corrigan and Strauss in a study of iron treatment for 
anemia Since then, several techniques based on the same principle have been 
described. This method involves a comparison of the medicine left in the patient's 
bottle and the quantity which should have been left if the medication had been taken. 
Though this method is being used extensively, it is not believed to be very accurate. 
6 
Patients may empty the pill box, or take all the remaining pills before their clinic 
visit. 
Drug Assay: The accuracy of this method depends in part on the half-life of the drug. 
Longer-acting indicators have been used, but testing will show only past ingestion 
and not frequency or dosing interval. These studies are very inconvenient and can be 
expensive. Some patients may object to having blood specimen taken, regarding this 
as unnecessary and intrusive. Again the value of assessing compliance in this way 
depends greatly on the reliability of the method by. which the drug is identified or 
quantified in body fluids (Biggs et al., 1976) 
Medication Event Monitoring System (MEMS): provides a computer chip in the cap of 
the medicinal bottle, information is recorded each time the bottle is opened. Data 
from the MEMS allows calculation of 1) the compliance rate, 2) prescribed 
frequency, and 3) prescribed interval. A study of adherence in patients taking 
antiretroviral therapy revealed that while the overall compliance rate was 82% to 
86%, more detailed measures of the fraction of doses taken at the prescribed daily 
interval (55-76%) and fraction of doses taken at the prescribed dosing interval (27%) 
were lower (Friedland G, JAMA, 1997). 
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METHODOLOGY 
Study Sample 
Patient population: Eligibility criteria for this study included age between 18 and 
74, current use of approved antiretroviral medications or Protease Inhibitors or use 
of approved medication for HIV-related complications and prophylaxis of 
opportunistic infections (for ·example,_ trimethoprim-sulfamethoxazole used in the 
prophylaxis of Pneumocystic carinii pneumorua), ~bility to read English, and positive 
HIV status. Patients (n=145) were recruited from three sites described below: 
1. The Miriam Hospital Immunology Center has the largest number of ambulatory 
visits of HIV seropositive individuals and serves the majority of HIV + women in 
Rhode Island. 
2. Stanley Street Treatment and Resources, which provides primary care for the 
indigent and intravenous drug using population in the greater Fall River 
Massachusetts area. 
3. Veterans Affairs Medical Center in Providence, RI, which currently provides 
care to approximately 60 HIV seropositive men. 
Data Collection: 
Patients meeting the above criteria who visited one of the three sites were asked to 
fill out a standardized questionnaire. The patients were told that the questionnaire was 
about how they think and feel about the HIV related medications that they were 
taking, and about different strategies that people use to take their medications. They 
had the choice to fill it at home and mail it in or return to the clinic, or fill it out right 
8 
/ 
--
at the clinic. They were also told they would receive a gift certificate of $20 after they 
had filled out the questionnaire. The data was collected during the year 1996-97. 
The survey questionnaire (identified by first 3 letters of mother's first name and date 
of birth) administered to patients included data on demographics, living 
arrangements, education, employment, income, insurance, social support, side effects, 
and psychological measurement scales. It was a self reported questionnaire. The 
questionnaires were checked for completen~ss. 
Measures and Variables assessed: · 
Patients were asked to complete questionnaire items concerning : 
Demographic: age, gender, years of education, income, insurance, number of people 
in household, current health status, employment. 
Mood Status: The scale was taken from the SHORT-FORM-36 HEAL TH SURVEY 
developed by Rand Corporation and John E. Ware,(1990). It was designed as a 
generic indicator of health status for use in population surveys and evaluative studies 
of health policy. This scale measured the following dimensions: 
General Mental Health, covering psychological distress & well-being (five item: 
questions b, c, d, f and h) 
Vitality, energy, or fatigue (four item: questions a, e, g, and i) 
The questions were measured on a six point likert scale from none of the time (score 
of 1) to all of the time (score of 6). The questions include: 
a Did you feel full of pep? 
b. Have you been a very nervous person? 
c. Have you felt so down in the dumps that nothing could cheer you up? 
9 
d. Have you felt calm and calm and peaceful? 
e. Did you have a lot of energy? 
£ Have you felt downhearted and blue? 
g. Did you feel worn out? 
h. Have you been a happy person? 
1. Did you feel tired? 
Scoring: Answers on questions a, d, e, h were recoded (i.e. score of 1 was changed to 
score of 6, score of 2 was changed to score of s· and so on) such that low values 
represent more favorable states. Further scores on question b, c, d, £: and h were 
summed up to get the score for each individuals General Mental Health. Similarly 
question a, e, g, and i was added to get the score on vitality, fatigue or energy. Finally 
transformed score on each of the two were obtained by the following formula 
Transformed scale = (actual score - lowest possible score) * 100 
Possible raw score range 
Clinical Characteristics: The following questions assessed clinical variables: 
1. Number of days in bed in the past two weeks 
2. Number of hospitalizations in the past year 
3. T-cell count last tested 
4. Pain interfering with work in the past 4 weeks. 
Item ( 4) measured the extent to which pain interfered with work in the past 4 weeks. 
It was measured on a 5- point likert scale (not at all - extremely). 
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Coping: This scale is taken from the WOC (ways of coping questionnaire) developed 
by Lazarus and Folkman (1984). The scale was revised in 1986 by Lazarus, Folkman, 
Dunkel-Schetter to make a 51 item questionnaire with 8 factors. This scale was 
further adapted by Dunkel-Schetter, Feinstein, Taylor, Falke to suit their study on 
cancer patients (WOC- cancer version). The responses on the items were measured on 
a five point likert scale rangin~ from never, rarely, occasionally, often, to very often. 
Finally, the five factors developed as .a remJlt of the factor loadings were : 
. 
Seek and Use Social Support: swnof item numbers 4, 34, 22, 20, 16, 49, 13, 31, 6, 
. . 
19, 1 
Cognitive Escape-Avoidance: sum of item numbers 7, 44, 45, 42, 43, 46, 8, 51, 12 
Distancing: sum of item numbers 40, 30, 33, 9, 10, 11, 50, 37, 15, 32, 48, 52 
Focus on the Positive: sum of item numbers 26, 27, 17, 41, 21, 28, 14, 47 
Behavioral Escape- Avoidance: sum of item numbers 29, 23, 24, 35, 39, 18, 5, 3, 25 
The description of the items is in the (Section VI of the appendix 
For this study, observations with more than 2 missing values on any of the 50 items 
was dropped. The final score on each factor was obtained by summing the scores on 
the items for that factor. 
Eg. Distancing= sum (QVI40 QVI30 QVI33 QVI9 QVIlO QVIll QVI50 QVI37 
QVI15 QVI32 QVI48 QVI52). 
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( Assessment of compliance: 
1. Number of Doses missed in the past three months: This was a self reported 
answer to the question " how many doses of medications have you missed in the past 
three months". Higher numbers indicated worse compliance. 
2. Temptation to skip medication: This scale was developed to measure self-
reported likelihood of non-co1!1pliance (Willey, C et al, manuscript in progress). The 
items on the temptation scale were based_ upon predictors of compliance from the 
literature and included situations that might affect you taking your protease inhibitors 
as directed. Responses for each situation rated how tempted you would be to skip 
your protease inhibitor medication. The responses were measured on a five-point 
likert scale (continuous) with 1 =not tempted to 5= extremely tempted. 
A few of the items under this includes: 
• When you feel good and you don't need it 
• When you are anxious about side effects 
• When you want to save on cost of medication 
• When your doctor doesn't seem interested in whether you take your medication 
• When you start feeling better 
3 subscales were developed: 
a. Temptation to skip medication due to side effects 
• When you are anxious about side effects 
• When you experience minor side effects 
• When you feel you should give your body a rest 
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• When you worry that the chemicals in the medication might harm or hurt your 
body 
b. Temptation to skip medication due to lack of support 
• When your family and friends don't seem concerned enough about your condition 
• When your doctor doesn't seem concern~d enough about your condition 
• When your insurance doesn't cover the cost of your medication 
• When you lose confidence in your doctbr: 
~ 
c. Temptation to skip medication When feeling good 
• When you feel good and think you don't need it 
• When your medical condition doesn't seem that bad 
• When it seems too complex to keep track of all your medications 
• When you aren't sure ifthe medicine is really helping you 
d. Total scale 
Score on each subscale was obtained by adding items under each subscale. 
For eg. Score on temptation to skip medication= sum (QV2 + QV6 + QV29 + QV30) 
Score on total scale may be obtained by summing the all the items under all the 
subscales. 
Data Analysis 
The above categories constitute the independent and dependent variables. Bivariate 
and multivariate statistics techniques were used to examine the association between 
the dependent and independent variables. The data was analyzed using the Statistical 
Analysis System (SAS) Version 6.09 on the IBM mainframe computer at the 
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University of Rhode Island. Pre-analysis screening procedures were used to assess 
normality, linearity and homoscedasticity. Residual scatterplots (difference between 
obtained and predicted DV scores) were obtained. Plots ofDV Vs IVs were plotted to 
check for outliers. PROC UNIV ARIA TE procedures were carried out to check for 
skewness and kurtosis. PROC COLLIN I VIF I TOL were the different collinearity 
diagonostic procedures carried out to check for possible cases of multicollinearity. 
Demographic variables "number of people in household" and "insurance" did not 
meet the above assumptions. "number of people -in household" had problems with 
outliers. Very high values were dropped from the study. A plot of DV Vs number of 
people in household showed a drop in DV value at number of people in household=2. 
Therefore this variable was categorized into two groups (1 person Vs 2+ people). The 
variable "insurance" was basically 10 categories of insurance type (eg. Blue cross, 
medicare etc). Since we were only interested in whether our patients had some 
insurance coverage to no insurance coverage and not what type of insurance, we 
created two new categories under this variable (no insurance Vs some insurance). 
The following variables were determined to be of interest and were further 
categorized for their use in the model: 
The dependent variables include the following: 
J. Number of doses missed in the past 3 -months: continuous (self-reported) 
2. Temptation to skip medication: continuous 
a. Total scale 
b. due to side effects 
c. due to lack of support 
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d. feeling good . 
Independent variables include: 
A. Demographic 
Age: categorical ~ 
< 25 years - 1 
25-34 years - 2 
35-44 years - 3 
-
45-54 years - 4 ;.. 
55 +years - 5 
Yean of education: categorical 
< 12 years - 1 
12 years - 2 
,../' 13-15 years - 3 
16 +years- 4 
Race : categorical 
White- 1 
Native Americans - 2 
Hispanic-3 
Asian-4 
African American - 5 
Others - 6 
Cu"ent Health Status : categorical 
Excellent - 1 
15 
Very Good-2 
Good-3 
Fair- 4 
poor- 5 
Gender: categorical 
Female - 1 
Male-2 
Employment: categorical 
Full-time - 1 
Part-time - 2 
Unemployed - 3 
Insurance : categorical 
No insurance - 0 
Some insurance - 1 
Income: categorical 
Less than $15,000 - 1 
$15,000 to $24,000 -2 
$25,000 to $34,000 -3 
$35,000 to 44,000 - 4 
45,000 or more - 5 
Number of people in household: categorical 
1 person - 1 
2+ person - 2 
16 
I B. Clinical 
bodily pain in past 4 weeks: categorical 
None- 1 
Very mild- 2 
Mild- 3 
Moderate-4 
Severe - 5 
Very Severe - 6 
. . 
Pain interfering with normal work in past 4 weeks: categorical 
Not at all- 1 
A little bit - 2 
Moderately - 3 
Quite a bit - 4 
Extremely - 5 
Number of days in bed in the past 2 weeks: continuous 
Number of hospitalization in the past year : continuous 
Mood Status and Coping 
General mental health: continuous (GMH) 
Fatigue: continuous (FAT) 
Seek and use social support : continuous (SSS) 
Cognitive Escape-Avoidance: continuous (CEA) 
Distancing : continuous (DIS) 
Focus on Positive: continuous (FOP) 
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Behavioral Escape-Avoidance: continuous (BEA) 
PROC GLM and PROC TTEST procedures were carried out to check if there were 
any significant differences between groups for the demographic variables. Here, the 
values of different demographic variables like age, 'education, race represents groups 
and the emphasis is on finding mean differences in Y between groups. 
PROC REG procedures (Standard multiple regression) were carried out for the 
following models. 5 models were run for ea,ch group of predictor variable. 
Models for Demographic characteristics: 
1. Temptation to skip medication for the side effect scale= age+ gender+ current 
health status + income + race + number of people in household + insurance + 
education. 
2. Temptation to skip medication for the lack of support scale = age + gender + 
current health status + income + race + number of people in household + 
insurance + education 
3. Temptation to skip medication for the feeling good scale= age+ gender+ current 
health status + income + race + number of people in household + insurance + 
education 
4. Temptation to skip medication for the total scale= age+ gender+ current health 
status + income + race + number of people in household + insurance + education 
5. number of doses missed in the past three months = age + gender + current health 
status+ income+ race+ number of people in household+ insurance+ education 
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Models for Clinical Characteristics: 
1. Temptation to skip medication for the side effect scale = bodily pain/past 4 weeks 
+ pain interference with work/past 4 weeks + number of days in bed + number of 
hospitalization. 
2. Temptation to skip medication for the lack of support scale= bodily pain/past 4 
weeks + pain interference_ with work/past 4 weeks + number of days in bed + 
number of hospitalization. 
3. Temptation to skip medication for the feeling good scale = bodily pain/past 4 
weeks + pain interference with work/past 4 weeks + number of days in bed + 
number of hospitalization. 
4. Temptation to skip medication for the total scale = bodily pain/past 4 weeks + 
pain interference with work/past 4 weeks + number of days in bed + number of 
hospitalization. 
5. number of doses missed in the past 3 months= bodily pain/past 4 weeks+ pain 
interference with work/past 4 weeks + number of days in bed + number of 
hospitalization 
Models for Mood Status and Coping: 
1. Temptation to skip medication for the side effect scale= GMH +FAT+ SSS+ 
CEA +BEA+ DIS +FOP 
2. Temptation to skip medication for the lack of support scale = GMH + FAT + SSS 
+ CEA +BEA+ DIS +FOP 
3. Temptation to skip medication for the feeling good scale= GMH +FAT+ SSS+ 
CEA +BEA+ DIS + FOP 
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( 4. Temptation to skip medication for the total scale= GMH +FAT+ SSS+ CEA+ 
BEA + DIS + FOP 
5. number of doses missed in the past 3 months= GMH +FAT+ SSS+ CEA +BEA 
+DIS +FOP 
The R2 values (variability in dependent variable that is accounted by the independent 
variable) were compared between the models. The standardized coefficient and p 
values were obtained. The sign on the beta1_v~lues were checked to see if they were as 
expected. 
The final step in the analysis of the research data was selection of the final model for 
predicting medication compliance. 
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RESULTS 
A total of 145 patients were enrolled in the study. 73 patients were on Protease 
Inhibitors, which comprised the study population. Three quaters of the study sample 
were male (77%). The median age was 39 years arid it ranged between 24-57 years. 
Seventy six percent (55/73) were white and only 6% were Hispanics. 8% were 
African Americans. The most common risk factors for HIV were homosexual life 
style 43% (29/73), heterosexual contact 32_o/q (22173) and intravenous drug use 25% 
(17/73). Most of the patients (87%) ~had some kind of insurance (Blue Cross, Ocean 
State, RIGHA, HCHP, other private insurers, HMO, Medicaid, Medicare, others). 
More than half lived with someone else (Husband or wife, intimate partner, other 
adults 18 or older, parents, grandparents, children under 18 or children over age 18). 
Half of the study population had an annual income of less than $15,000. 800/o (57 /73) 
had completed at least high school education. 
A. Relationship between Demographic Characteristics and Temptation to skip 
Protease Inhibitors: 
Table 1 presents the demographic characteristics of the study sample (n=73). General 
linear model procedure was carried out to check if there was any significant 
difference in temptation to skip medications due to demographic characteristics. 
Temptation to skip medication did not ,differ with age, race, years of education, 
income, number of people in household, insurance and the current health status. 
B. Relationship between Demographic characteristics and number of doses of 
Protease Inhibitors missed in the past three months: 
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Table 2 represents the demographic characteristics of patients with number of doses 
missed in the past three months. GLM procedures indicated that the number of doses 
missed did not differ with age, race, years of education, income, current health status 
or number of people in household. But it differed •:with insurance and gender. The 
number of doses missed was higher if a person had insurance coverage (p<0.006). 
Also females showed higher number of missed doses (p<0.0011). 
C. Table 3 summarizes the results of Multiple Regression for the Clinical 
predictors of Temptation to skip medication forlQtal scale: 
In Table 3 the negative sign on B indicates a negative association between the 
number of days in bed during the past two weeks, number· of hospitalization in the 
last one year, T-cell count last tested and the temptation to skip Protease Inhibitors. 
However none of these associations were significant. Pain interfering with work in 
the past 4 weeks was significant at 0.05 level of significance. The model accounted 
for 18% of variation. 
D. Table 4 summarizes the results of Multiple Regression for the Clinical 
predictors of Temptation to skip Protease Inhibitors for the side-effect scale: In 
Table 4 the number of days in bed during the past two weeks and the number of 
hospitalizations in the past one year were negatively associated with the temptation to 
skip medication due to side-effects. Pain interfering with work in the past four weeks 
again showed significance at the 0.05 level of significance. The model accounted for 
7% of variation. 
E. Table 5 summarizes the results of Multiple Regression for the Clinical 
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( predictors of Temptation to skip protease inhibitors for the lack of support 
scale: 
In Table S, the number of days in bed during the past two weeks and T cell count last 
tested were negatively associated to the temptation to skip medication due to lack of 
support. None of the Clinical predictors were significant at 0.05 level of significance. 
This model accounts for only 3% of variance. 
F. Table 6 summarizes the results of multiple regression for the Clinical 
predictors of Temptation to skip protease inhibitors for the Feeling good scale: 
Number of days in bed during the past two weeks, Number of hospitalization in the 
past year and the T cell count last tested were negatively associated to the temptation 
to skip medication when feeling good. Pain interfering with work in the past 4 weeks 
showed significance with a p- value ofless than 0.0004. This model accounts for 18% 
of the variance. 
G. Table 7 summarizes the results of multiple regression for the Clinical 
predictors of number of doses of Protease inhibitors missed in the past three 
months: 
Negative sign on the B values indicate that the clinical predictors are negatively 
associated to the number of doses missed in the past three months. None of the 
predictors showed significance at the 0.05 level of significance. The overall model 
accounted for 3% of variation. 
H. Table 8 summarizes the results of multiple regression for the mood status 
and coping predictors of Temptation to skip Protease Inhibitors for the total 
scale: 
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Focus on positive was negatively associated with the Temptation to skip Protease 
Inhibitors for the total scale. None of the variables were significant at the 0.05 level 
of significance. This model accounted for 25% of the variance. 
A. Table 9 summarizes the results of multiple regression for the mood status 
and coping predictors of Temptation to skip Protease Inhibitors for the side-
effect scale: Validity, energy and fatigue; social support and focus on positive were 
negatively associated to temptation to '.skip ,Protease Inhibitors due to side-effects. 
Variables did not show significance at 0.05 level ofsignificance. Model accounted for 
9% of the variation. 
B. Table 10 summarizes the results of multiple regression for the mood status 
and coping predictors of temptation to skip Protease Inhibitors for the lack of 
support scale: 
Validity, energy and fatigue; seek and use social support, cognitive escape-
avoidance, distancing, Focus on positive were negatively associated to the temptation 
scale. General mental health & behavioral escape avoidance showed significance at 
0.05 level of significance. The model accounted for 25% of variance. 
C. Table 11 summarizes the results of multiple regression for the mood status 
and coping predictors of Temptation to skip Protease Inhibitors for the Feeling 
good scale: 
Focus on positive and Behavioral escape- avoidance are negatively associated to the 
temptation scale. None of the variables showed any significance at the 0.05 level of 
significance. The model accounts for 20% variance. 
D. Table 12 summarizes the results of multiple regression for the mood status 
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and coping predictors of number of doses of Protease Inhibitors missed in the 
past three months: 
Seek and use social support, cognitive escape avoidance, distancing are negatively 
associated to the number of doses missed. None of the variables showed significance 
at the 0.05 level of significance. The model accounted for 11 % of variance. 
E. Table 13 summarizes the results of multiple regression for the Demographic 
predictors of Temptation to skip Medica~i~n for the total scale: 
Age, years of education, . number of people in ho~hold and annual income were 
negatively associated to the Temptation to skip medication for the total scale. number 
of people in the household showed significance at the 0.05 level of significance. The 
model accounted for 26% of variance. 
F. Table 14 summarizes the results of multiple regression for the Demographic 
predictors of Temptation to skip Protease Inhibition for the side-effect scale: 
Gender, race, number of people in household, years of education are negatively 
associated to the Temptation to skip Protease Inhibitors for the side-effect scale. None 
of the variables showed significance at the 0.05 level of significance. The model 
accounted for 26% of the variability. 
0. Table 15 summarizes the results of multiple regression for the Demographic 
predictors of Temptation to skip Protease Inhibition for the lack of support 
scale: 
Age, gender, race, number of people in household and years of education were 
negatively associated to the Temptation scale. None of the demographic variables 
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( showed significance at the 0.05 level of significance. The model accounted for 13% 
of the variability. 
P. Table 16 summarizes the results of multiple regression for the Demographic 
predictors of Temptation to skip Protease Inhibi'tion for the feeling good scale: 
Race, number of people in household, annual income and years of education were 
negatively associated to th~ Temptation scale. None of the variables showed 
significance at the 0.05 level of significance. The model accounted for 15% of the 
variability. 
Q. Table 17 summarizes the results of multiple regression for the Demographic 
predictors of the number of doses of Protease Inhibitors missed in the past three 
months: 
Age, gender, current health status, race, years of education, annual income, insurance 
were negatively associated to the number of doses missed in the past three months. 
Gender showed significance at the 0.05 level of significance. The model accounted 
for 27% of the variability. 
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Table !:Characteristics of the patient population by Demographics for the 
T t f t ki P t I h"b"t emJ!! a 100 0 S ~ ro ease n I 1 ors: 
Demographic Variables ( % ) n mean 
Age 
>25yrs 1 (1%) 19 
25-34yrs 20 (27%) 
, 
25.3 F=0.69 
35-44yrs 28(38%) 23.6 p<0.6032 
45-54yrs 22 (30%) 23.68 R2=0.0445 
55+yrs 2 (3%) 19 
Gender 
Female 16 (25%) 24.2 F=l.08 
Male 48 (75%), 23.7 p<0.7981 
Race -;.. 
White, non-Hispanic 55 (76%) . 23.9 .. 
Hispanic 4 (6%) 30 F=l.78 
African American 6 (8%) 26.25 p<0.1710 
Other 7 (10%) 20.14 R2=0.0807 
Years of Education 
<12yrs 15 (21%) 25.5 F=l.11 
12yrs 22 (31%) 24.3 p<0.3542 
13-15yrs 20 (28%) 21.8 R2=0.0532 
16+yrs 15 (21%) 24.9 
Income 
Less than $15,000 40 (57%) 24.1 
$15,000 to $24,000 12 (17%) 24.9 F=0.32 
$25,000 to $34,000 6(9%) 23.8 p<0.8603 
$35,000 to $44,000 9 (13%) 21.8 R2=0.0222 
$45,000 or more 3(4%) 22.7 
number in household 
1 person 16 (35%) 26.5 F=l.86 
2+~o.£!e 30 (65%) 21.4 p<.626 
Insurance 
No 9 (13%) 22.0 F=l.56 
Some 63 (87°/~ 24.1 j!_<0.6051 
Current Health Status 
Excellent 8 (11%) 24.1 ' 
Very Good 13 (18%) 23.5 F=0.62 
Good 39 (53%) 23.1 p<0.6484 
Fair 12 (16%) 26.6 R2=0.0404 
Poor 1 (!%1 25.0 
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Table 2:Characteristics of the patient population by Demographics for the 
N b f d d . th t 3 th um ero oses m1sse ID e J!_aS mon s: 
Demographic Variables ( % ) n mean 
Age 
>25yrs 1 (1%) 8 
25-34yrs 20 (27%) 5.7 F=0.49 
. 
35-44yrs 28(38%) 4.2 p<0.7457 
45-54yrs 22 (30%) 2.9 R2=0.0309 
55+yrs 2 (3%) 0.0 
Gender 
Female 16 (~) 8.0 F=3.43 
Male 50_1o/or 2.9 _l!_<0.0011 
Race 
-;.. 
White, non-Hispanic 55 (76%) 4.8 
Hispanic 4 (6%) 2.7 F=0.40 
African American 6 (8%) 2.8 p<0.7516 
Other 7 (10%) 1.5 R2=0.0192 
Years of Education 
<12yrs 15 (21%) 7.2 F=l.47 
12yrs 22 (31%) 4.3 p<0.2323 
13-15yrs 20 (28%) 1.4 R2=0.0673 
16+yrs 15 (21%) 5.2 
Income 
Less than $15, 000 40 (57%) 5.3 
$15,000 to $24,000 12 (17%) 2.6 F=0.60 
$25,000 to $34,000 6(9%) 1.8 p<0.6664 
$35,000 to $44,000 9 (13°/o) 5.1 R2=0.0382 
$45,000 or more 3 (4%) 0.7 
number in household 
1 person 16 (35%) 2.4 F=3.40 
2+ _£._eo~e 30 (65%) 4.8 _p_<.016 
Insurance 
No 9 (13%) 2.1 F=13.56 
Some 63187°1~ 4.9 j!_<0.0006 
Current Health Status ' 
Excellent 8 (11%) 2.6 
Very Good 13 (18%) 8.7 F=l.30 
Good 39 (53%) 3.3 p<0.2811 
Fair 12 (16%) 3.5 R2=0.0784 
Poor 1 (!%) 0.0 
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Table 3: Clinical Predictors Of Temptations To Skip 
Medication for The Total Scale 
Independent Standard Standard 
Variables Coefficient Error 
• 
number of days in -0.252070 0.26608237 
bed in the past two 
weeks 
number of -0.150S87 0.41150700 
hospitalization in 
the l!_ast_year ' 
-,.. 
T-cell count last -0~169805 o.7695P260 
tested 
Pain interference 2.259875 0.56567161 
with work in the 
_E_ast 4 weeks 
MODEL R2 = 0.1844 
29 
p 
0.4000 
0.7827 
0.6711 
0.0008 
Table 4:Clinical Predictors of Temptations to Skip 
Medication for the Side Effect Scale 
Independent Standard Standard ' 
Variables Coefficient Error 
number of days in -0.029014 0.10903916 
bed in the past two 
weeks 
~ 
I 
number of -0.226164 0.180il361 
hospitalization in -
-
the past year --
T-cell count last 0.173197 0.31605649 
tested 
Pain interference 0.490655 0.23056680 
with work in the 
_past 4 weeks 
MODEL R2 = 0.0765 
30 
p 
_10.051 
0.7910 
0.2134 
0.5854 
0.0369 
Table 5: Clinical Predictors of Temptations 
To Skip Medication for the Lack of Support Scale 
Independent Standard Standard p 
Variables Coefficient Error 
' 
number of days in -0.066172 0.10691938 0.5383 
bed in the past two 
weeks 
number of 0.066261 0.16535509 0.6900 
hospitalization in ~ : 
the l!_ast_x.ear . 
-
-
T-cell count last -0.184734 0.30920719 0.5524 
tested 
Pain interference 0.275566 0.22730277 0.2301 
with work in the 
_p_ast 4 weeks 
MODEL R2 = 0.0329 
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Table 6: Clinical Predictors of Temptations 
To Skip Medication for the Feeling Good Scale 
--"'-
Independent Standard Standard p 
Variables Coefficient Error 
number of days in -0.104082 0.21505136 0.6299 
bed in the past two 
weeks ~ 
I 
. j 
. 
number of -0.050817 0.35522722: 0.8867 
hospitalization in -. -
the _p_ast year 
T-cell count last -0.420103 0.62333918 0.5026 
tested 
Pain interference 1.686873 0.45473300 0.0004 
with work in the 
_past 4 weeks 
MODEL R2 = 0.1831 
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Table 7:Clinical Predictors of Number of Doses 
Missed In the Past Three Months 
Independent Standard Standard 
Variables Coefficient Error 
-0.219782 0.49928973 
number of days in 
bed in the past two 
weeks 
-0.521501 0.84307291 
number of 
hospitalization in 
the J!_ast year ~ 
'· ' 
-0.471129 1.22601610_ 
T-cell count last -
- · tested 
-0.574209 0.91188786 
Pain interference 
with work in the 
_p_ast 4 weeks 
MODEL R2 = 0.0351 
33 
p 
0.6614 
0.5386 
0.7022 
-
0.5314 
Table 8:Mood Status & Coping Predictors Of 
Temptations to Skip Medication for the Total Scale 
Independent Standard Standard 
Variables Coefficient Error 
General mental 0.057523 0.06838932 
Health 
Validity, energy & 0.081699 0.07096276 
fat!g_ue 
Seek and use social 0.035140 0.126165 
SU 1!.l!_Ort 
Cognitive Escape- 0.167219 0.145214 
Avoidance I 
Distancing 0.152464 0.119712 
-;.. 
-
Focus on the -0.208724 0.141352 
~ositive 
Behavioral Escape- 0.100838 0.152454 
Avoidance 
MODEL R2 = 0.2460 
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p 
0.2041 
0.7991 
0.7065 
0.2363 
0.2973 
0.1589 
0.4670 
Table 9:Mood Status & Coping Predictors Of 
Temptations to Skip Medication for the Side Effect Scale 
Independent Standard Standard p 
Variables Coefficient Error 
General mental 0.003501 0.02930638 0.5122 
Health • 
Validity, energy & -0.003084 0.03040916 0.1722 
fatigue 
Seek and use social -0.003943 0.04307266 0.9745 
support 
Cognitive Escape- 0.018441 ().05429477 0.6684 
Avoidance I 
Distancing 0.040685 0.0458562~ 0.5441 
-
.. 
Focus on the -0.028221 0.05260424 0.6384 
_p_ositive 
Behavioral Escape- 0.068619 0.05555417 0.1920 
Avoidance 
MODEL R2 = 0.0933 
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Table lO:Mood Status & Coping Predictors of Temptations 
To Skip Medication for the Lack of Support Scale 
Independent Standard Standard p 
Variables Coefficient Error 
General mental 0.065227 0.02493562 0.0151 
' Health 
Validity, energy & -0.011578 0.02587393 0.7744 
fat!.g_ue 
Seek and use social -0.069824 0.03822089 0.0668 
su_p_p_ort 
Cognitive Escape- -0.010692 0.04399168 0.8506 
Avoidance ' 
Distancing -0.015112 0.03626603: 0.5991 
. 
Focus on the -0.023162 0.04282165 0.6071 
_E_ositive 
Behavioral Escape- 0.131255 0.04618492 0.0059 
Avoidance 
MODEL R2 = 0.2575 
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( Table ll:Mood Status & Coping Predictors of Temptations 
To Skip Medication for the Feeling Good Scale 
Independent Standard Standard p 
Variables Coefficient Error 
General mental 0.027457 0.05662832 
• 
0.8371 
Health 
Validity, energy & 0.084715 0.05875920 0.8862 
fat!g_ue 
Seek and use social 0.129291 0.08058121 0.0838 
su_p_p_ort 
Cognitive Escape- 0.173044 0.10157577 0.0994 
Avoidance I 
Distancing 0.143841 0.08578884: 0.1037 
. 
Focus on the -0.175670 0.09841308 0.0791 
_Q_ositive 
Behavioral Escape- -0.060387 0.10393187 0.5978 
Avoidance 
MODEL R2 = 0.2058 
37 
( Table 12:Mood Status & Coping Predictors of Number 
Of Doses Missed in the Past Three Months Medication 
Independent Standard Standard 
Variables Coefficient Error 
General mental 0.079499 0.10050718 . 
Health 
Validity, energy & 0.108293 0.10143939 
fat!g_ue 
Seek and use social -0.068747 0.15851851 
SUJ>j>_Ort 
Cognitive Escape- -0.079289 0.19385247 
Avoidance ! 
Distancing -0.194862 0.17043714· 
. 
Focus on the 0.344344 0.20782860 
_p_ositive 
Behavioral Escape- 0.075140 0.20920783 
Avoidance 
MODEL R2 = 0.1161 
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p 
0.4324 
0.2905 
0.6662 
0.6841 
0.2580 
0.1033 
0.7209 
Table13: Demographic Predictors of Temptation to Skip Medication 
For Total Scale 
Independent Standard Standard Error 
variable Coefficient 
Age 0.0086 0.11860 0.9426 
1 (continuous) 
Gender -0.8833 2.08232 0.6739 
Current Health 0.8056 1.12782 0.4795 
Status ( ca~orica!}_ 
Race (categorical) -0.0235 
'. 
0.55070 0.9661 
f 
Years of Education -0.4451 0.32()53 0.1732 
_(continuou~ -
number in -4.9342 2.00558 0.0187 
household Jl vs 2+1 
Annual Income 0.0738 0.80883 0.9278 
_(cate_g_orical) 
Insurance 4.9699 3.31847 0.1427 
(none Vs som~_ 
MODEL R2=0.2685 
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Table 14: Demographic Predictors of Temptation to Skip Medication 
For Side Effect Scale 
Independent Standard Standard Error 
variable Coefficient 
Age 0.083068 0.0415 6 0.0523 
(continuous) 
Gender -1.408103 0.708451 0.0536 
Current Health 0.155997 0.38977 0.6911 
Status 1cat~orical) 
Race -0.095403 I :0.194311 0.6261 
(categorical) 
-
Years of Education -0.21097 0.112697 0.0683 
1continuous}_ 
number in -0.823432 0.679762 0.2327 
household 11 vs 2+1 
Annual Income 0.33747 0.289008 0.2497 
(cat~orica!}_ 
Insurance 1.60375 1.086704 0.1476 
1none Vs some) 
MODEL R2=0.2667 
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Table 15: Demographic Predictors of Temptation to Skip Medication 
For Lack of Support Scale 
Independent Standard Standard Error 
variable Coefficient 
Age -0.00791 0.03790 0.8357 
_(continuous) ' 
Gender -0.55259 0.66255 0.4095 
Current Health 0.370345 0.36340 0.3146 
Status ( ca~orica!)_ 
Race -0.24958 0.17230 0.1557 
_{_cat~orica!)_ I 
Years of Education -0.08248 0.10326 0.4294 
_(continuou~ -
number in -0.59231 0.62711 0.3509 
household (1 vs 2+1 
Annual Income 0.111573 1.067611 0.9173 
( ca~orica!}_ 
Insurance 0.10123 0.260526 0.6998 
(none Vs somrj_ 
MODEL R2=0.1321 
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Table 16: Demographic Predictors of Temptation to Skip Medication 
For Feeling Good Scale 
Independent Standard Standard Error 
variable Coefficient 
Age 0.03845 0.09277 0.6806' 
(continuous) • 
Gender 0.27638 1.57834 0.8618 
Current Health 0.82236 0.87711 0.3538 
Status (cat~orical) 
Race -0.23059 0.42361 0.5891 
~ 
J_cat~orica!}_ I 
Years of Education -0.24517 0.25349 0.3390 
(continuous) -
number in -2.26079 1.49042 0.1368 
household (1 vs 2+1 
Annual Income -0.48302 0.650116 0.4610 
( cate__g_orical) 
Insurance 1.349710 2.43795 0.5828 
(none Vs somel 
MODEL R2=0.1532 
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Table 17: Demographic Predictors of Number of Doses Missed In 
The Past Three Months 
Independent Standard Standard Error 
variable Coefficient 
Age -0.087099 0.15805735 0.5851 
1continuous) 
Gender -5.873565 2.75002781 0.0398 
Current Health -0.633602 1.44894597 0.6646 
Status J_cate_g_orica!}_ 
Race -0.894087 ~ 1.44894597 0.2491 
' J_ca~orica!}_ 
Years of Education -0.339226 . 0.40781591 0.4112 
J_continuou~ 
number in 1.030172 2.58618504 0.6928 
household J_l vs 2+1 
Annual Income -0.882132 1.03618448 0.4004 
( cat~orical) 
Insurance -1.272744 4.51846837 0.7799 
_{_none Vs some) 
MODEL R2=0.2773 
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( Summary Table of Results 
Significant Predictors of Temptation to Skip Protease Inhibitors & number of 
doses missed 
D d t . bl eJ>_en en vana es~ 
T 1 scale* T1 scale* T3 scale* Total scale * number 
of doses 
'. missed* I 
Clinical Pain No predictors Pain Pain No 
Characteristics interfering interfering interfering predictor 
with work "With work with work in 
in the past in the past the past 4 
4 weeks 4 weeks weeks 
Demographic No No predictor No number of Gender 
predictor predictor people Ill 
household 
Mood Status No General No No predictor No 
and Coping predictor Mental health predictor predictor 
Behavioral 
Escape-
Avoidance 
(*)=See Footnote 
* T 1 = Temptation to skip medication for the side-effect scale 
* T 1 = Temptation to skip medication for the lack of support scale 
* T3 =Temptation to skip medication for the feeling good scale 
* Total scale= Temptation to skip medication for the total scale 
* Number of doses missed= number of doses missed in the past 3 months 
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( DISCUSSION 
This study examined three predictors of compliance. The predictors examined were 
demographics, clinical and mood status and coping. Temptation to skip Protease 
Inhibitors and the number of doses missed in the past three months were two 
measurements employed to measure compliance. In this section, the independent 
variables will be analyzed individually to study their impact on medication 
compliance. 
A. Demographics characteristics: 
Demographic predictors; age, gender, current health status, race, number of people in 
household, insurance, and income could not predict the temptation to skip protease 
inhibitors for the side-effect scale, lack of support scale and feeling good scale. 
This conclusion was in accordance with a number of studies done in the past. 
Demographic variable " number of people in household" was a significant predictor 
of temptation to skip medication for the total scale (p<O.O 1 ). Plot of temptation scale 
Vs number of people in household shows that there was a drop in the mean 
temptation score if there were 2 or more people in household. This could be due to 
availability of good social support. Family and friends can play a crucial role in 
providing encouragement for achieving health goals. They can provide 
emotional/informational, tangible, affectionate, and positive social interaction 
support, which could make the patient want to feel better and take his medication 
regularly. 
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This study contradicts studies by Sherbourne on social support. She has emphasized 
that a single item measure of number of close friends and relatives cannot predict 
adherence, suggesting that it is the quality of relationship rather than quantity of 
supports that influence adherence. 
Demographic variable "gender" was a significant predictor of number of doses 
missed in the past three months (p<0.03). Mean number of doses missed for females 
was significantly higher than the males CP.:::0.001). This could be because lilV + 
women are known to express great distress and coric~m about familial issues such as 
pregnancy, transmission to lilV to their children and caring for their children. The 
experience of the disease may bring on different types of stressors. Also HIV-infected 
women have been shown to be more depressed and anxious as compared to lilV + 
men. This state of mind could have caused higher number of doses to be missed by 
females than by males. 
Studies in past has shown no consistent association between gender and compliance. 
B. Mood Status and Coping: 
Mood Status and Coping could not predict the temptation to skip protease inhibitors 
for the side-effect, feeling good, total scale and the number of doses missed in the 
past three months. General mental health ,(p<0.01) and Behavioral escape-avoidance 
(p<0.006) significantly predicted the temptation to skip Protease inhibitors for the 
lack of support scale. This shows that lilV + patients who were tempted to skip 
medication due to lack of support were using Behavioral Escape-Avoidance as their 
pattern of coping. This factor is known to involves behavioral signs of avoidance such 
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as social withdrawal, drug use, and impulsivity. HIV+ patients may suffer from 
specific fears such as abandonment, pain, death, and exposure to homosexuality, 
bisexuality, drug use, prostitution, or unsafe sexual activity. They therefore tend to 
live alone in an attempt to conceal their illness. Eventually since they lack social 
support, they try to withdraw themselves fi:om society and engage in activities like 
drug use etc. This result supports the conclusion by Dunkel-Schetter. Dunkel-Schetter 
studied the coping patterns of cancer patients and found that people who coped by 
. 
behavioral escape-avoidance were alSo more likely'"to live alone. 
General mental health was another predictor of temptation to skip protease inhibitor 
for the lack of support scale. It's a measure of psychological distress and well being. 
Higher scores represent favorable states while lower scores indicate higher 
psychological distress and depression. Since general mental health was significantly 
associated to the temptation to skip protease inhibitor for the lack of support scale, 
patient could be suffering from psychological distress and eventually getting tempted 
to skip medication. This conclusion was in accordance with the results of work by 
Nina Singh. She found that non-compliant patients demonstrated significantly greater 
psychological distress as assessed by standard psychological tests. 
C. Clinical: 
Pain interfering with work in the past four weeks significantly predicted temptation to 
skip protease inhibitors for the side effect scale (p<0.03), total scale (p<0.0002), and 
feeling good scale (p<0.0004). Pain can have a physical and emotional impact on a 
person. It can causes limiting activities of daily living or cause psychological 
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responses such as depression, agitation and decreased alertness. Thus, we can expect 
an mv + individual experiencing pain to be physically incapable of talcing his 
medication or psychologically depressed due to pain to want to talce his medication. 
D. Final Regression Model: 
The regression model with all the variables that best explained the dependent variable 
was defined as below: 
Temptation to skip medication for the total scali := 22.1674 - 4.8519 (number of 
people in household) - 0.0907 (behavioral escape avoidance) + 0.2091 (general 
mental health) - 0.0401 (pain interfering with work in the past 4 weeks) 
This model had a strong F value of ( 4.292) with a significant p (0.006). These 
predictors accounted for nearly 33% of variability. 
A backward elimination regression procedure was carried out. The equation started 
will all the 4 IVs entered and they were deleted one at a time if they did not contribute 
significantly to regression. The complete model had an R2 value of 0.3290. The 
variable pain interfering with work in the past 4 weeks got eliminated first. There was 
no change in the R2 value with this elimination. Next, the variable behavioral escape 
avoidance was dropped from the model This caused the R2 value to drop by 0.006. 
The final R2 value with number of people in household and General mental health 
was 0.3229. These were the only 2 significant predictors of Temptation to skip 
protease inhibitors. 
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E. Interactions: 
An effort was made to check if temptation to skip medication due to psychological 
distress was affected at different levels of pain. The following model was developed: 
Temptation to skip Protease Inhibitor for total scale = Pain interfering/4weeks + 
GMH + Pain interfering/4week*GMH. 
The interaction term, "pain*GMH'' did hot1.show significance at the significance level 
' 
0.05 suggesting that there was no interaetion between psychological distress and pain 
F. Limitations 
Self reported data: People may be inaccurate in reporting their behavior There may 
be multiple influences on them in terms of their ability and desire to provide a valid 
response. These factors may include clarity of questions, setting, memory, literacy, 
and mood status. 
Measurement : There seems to be no gold standard or satisfactory way to measure 
compliance, but the questionnaire has been designed to cover every aspect of 
patient's moods, disease status, coping, demographics, temptations scale etc. which 
can help us identify the predictors of compliance. The second measure of compliance 
used in our study was the number of doses missed in the past 4 weeks. This does not 
seem to be a very good measure of compliance. This may be because it is a single 
item measure and depends totally on patient recollection and memory. 
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( 
) . 
Measurement issues related to timing: This data was collected when protease 
inhibitors were first introduced to the market, so patterns of compliance may be 
different now than they were then. 
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CONCLUSIONS 
The results of this study on predictors of compliance of AIDS patient on Protease 
Inhibitors have provided a profile of predictors of compliance. The findings of this 
study are in accordance with a number of studies on predictors of compliance for HIV 
and other chronic disease states. Temptation to skip medication is a very new concept 
of compliance measurement. Results of these studies have shown that this scale could 
be a very good instrument to measure compliance. 
Through bivariate and multivariate· statistical procedures, a number of significant 
predictors of compliance were identified. The factors that appeared to predict 
compliance best were number of people in household, gender, general mental health, 
pain interfering with work in the past four weeks and behavioral escape avoidance. 
The other demographic variables like age, race, income, insurance, current health 
status had little association with compliance. This finding is consistent with results 
obtained from other studies. Though gender was one of the significant predictors of 
compliance, studies in the past haven't found any consistent association between the 
two. 
General mental health and number of people in household were two variables that 
best predicted compliance in our HIV patients. They accounted for major part of the 
variance in the temptation to skip medication scale. The negative relationship 
between the Temptation scale and the number of people in the household wasn't 
unexpected. Also, the results have shown that the higher the psychological distress 
the higher was the temptation to skip medication. This again wasn't surprising as 
many psychological factors have been associated with non-compliance. 
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l 
Compliance with Protease Inhibitors is a very significant problem because of the fear 
of development of resistance. This data has shown that psychological distress was a 
significant problem with the non-compliant HIV patients on Protease Inhibitors. 
Since illness like psychological distress and depression are often treatable, health care 
providers must provide appropriate treatment and counseling to these patients. These 
findings also suggested the importance of social support for compliance behavior. 
Health care providers should educate f~ly members about the psychological 
condition of this group of people and how social support can improve their compliant 
behavior significantly. An awareness of the factors associated with compliance can 
enable health care providers to identify those at risk for noncompliance behavior. 
They can then carry out extensive compliance-enhancing counseling programs and 
help reduce the impact ofthis problem. 
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• Questionnaire 
• Plots 
__ /" 
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Managing Your Medications Questionnaire 
Please answer thefollowing questions thoughifully and completely. This questionnaire is 
about how you think andfeel about the mv related medications that you are taking, and 
about the different strategies that people use to take their medications. It will take about 
45 minutes for you to fill this out. You may fill it out at home and mail it in or you may 
return it to this clinic. When you turn it in, we will give you a gift certificate for $20 to 
thank you for your participation. If you have the time to fill it out here, you may turn it in 
to the person who !tanded it to you, and receil;Je your gift certificate now. 
CODE FOR THIS QUESTIONNAIRE: 
A) What are the first 3 letters of your .mother's first narnr? 
Bl What is your birth date? 001[]01(]0 
mm dd yy 
SECTION I 
BACKGROUND INFORMATION 
Titefirst section of this questionnaire asks apout your background. 
- Please circle or fill in the correct response for each question. 
1. What is your age? DO years 
2. What is your gender? M F 
3. How would you describe your current health status? (Please check one answer) 
0 Excellent 0 Very Good 0 Good 0 Fair 0 Poor 
(1/1 ·3) 
(1/4·9) 
~ (1/10-11) 
(1/12) 
4. Which of the following best describes your ethnic background? (1/131 
0 White, non-Hispanic 0 Hispanic 0 African American 
0 Native American 0 Asian 0 Other· 
5. How many years of education have you finished? OD 11114-1s1 
6. Do you currently work either part-time or full time? 
0 Full-time 0 Part-time 0 1 am not currently employed 
7. Do you live by yourself or with other people? 
0 By myself 0 With others 
8. If you live with others. how many (besides you) are In your household? 00 
9. If you live with others. what Is their relationship to you? (Check all lhat apply) 
0 Husband or wife 0 Grandparents 
0 Intimate partner 0 Children under age 18 
0 Other adults 18 or older 0 Children over age 18 
0 Parents 
Uniucrslty of Rhode Island. 0199G 
57 
11/IGJ 
(1/17) 
(1/18·19) 
(1/20-26) 
( 10. Do you have any children? If so. how many? (If none. put 0) DD 
l 1. Do any of your adu It children live nearby (within a half hour drive)? 
D Yes 0 No 0 Not applicable 
12. How many of your family or friends can you count on for emotional support? OD 
13. How many of your family or friends can :you count on for financial help? 0 0 
14. How many of your fall)!!Y or friends can you count on for physical assistance. 
or a place to stay? 0 LJ : 
15. Do you feel confident that your family or friends will continue to help you with 
your everyday needs? 
D Very confident 
D Fairly confident 
0 .Somewhat confident 
D Less than somewhat confident 
0 Not at all cortlldent 
~· 
(1/27·28) 
(l/29) 
(1/30·31) 
(1/32-33) 
(1/34-35) 
(1/36) 
16. If you were to need more help with every day needs. do you feel co.nfident that your family or 
friends could provide it? · (1/37) 
0 Very confident 
0 Fairly confident 
0 Somewhat confident 
D Less than somewhat confident 
D Not at all confident i. 
17. How many of your family & friends have you told about your HIV infection? 
0 None 0 Less than half 0 About half 0 More than half 0 All 
18. What type of health insurance coverage do you currently have? 
0 NONE 
0 Blue Cross 0 HCHP 0 Medicaid 
0 Ocean State 0 Other private insurer 0 Medicare 
0 RIGHA 0 HMO 0 Other 
19. Which of the following best estimates your total (family) income during the 
past 12 months? 
0 Less than $15,000 
0 $15.000 to $24,000 
0 $25.000 to $34.000 
0 $35,000 to $44.000 
0 45.000 or more 
20. About how far do you live from this treatment center? 
0 Within walking distance 
0 Within a ten minute drive or less 
0 Within a twenty minute drive or less 
D Within a thirty minute drive 
D More than thirty minutes away 
University of llhodc Island. Q 1996 
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(1/38) 
(1/39-48) 
(1/49) 
(1/50) 
2 1. When you h ave quesUons about m ed icaUons for you r HIV infection. who do you 
u s ua lly ask? (Please check all Uwt apply) 
0 Ph a rma cis t 0 Other persons with Hrv infecUon 
0 Phys icia n 0 Family membe rs 
0 Social Worker 0 Friends 
0 Nurse 0 Other: please speclfy - ------------
(I/SI-SS) 
(1/59-78) 
22. Which h ealth care provider is most helpful to you in taking your medications as directed? (1/79) 
0 Nurse 
0 Pharmacist 
0 Physician 
0 Social Worker 
0 Other: please specify 1211-201 
23_ Is there someone living with. you or close to you who helps or reminds you to take your 
medications on time? 121211 
0 Yes 0 No 
24. How much bodily pain have you had during the past four weeks? 121221 
0 None 0 Moderate 
0 Very mild 0 Severe 
0 Mild 0 Very Severe 
25. During the past 4 weeks. how much did pain interfere with your normal work (including both 
work outside the home and housework)? (2/231 
0 Not at all 0 A little bit 0 Moderately 0 Quite a bit 0 Extremely 
26. During th.e past two weeks. how many days did you stay in bed all or most 
of the day? 00 (2/24-25) 
27. How many times have you been hospitalized in the past year? (Ij none. put OJ 0 0 (2/26-27) 
28. These questions are _about how youfeel and how things have been with you during the past 4 
weeks. 
For each question. please give the one answer that comes closest to the way you have beenf eeling. 
How much of the time during the past 4 weelcs __ _ 
NONE 
OF THE 
TIME 
A LITTLE 
BIT OF THE 
TIME 
SOME ACOOD 
OF THE _ BIT OF THE 
TIME Tll\~ 
MOST 
OF THE 
TIME 
ALL 
OF THE 
TIME 
~lmBiir~~JJr.&rfitfliifllltJIJ?JlJ~JWlt~~~l•Jlt@:?~f~~F~g~ ~W. <2 1281 
b . Have you been a very nervous O O 0 0 0 0 
person? (2/291 
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(2/30) 
(2/31) 
(2/32) 
(2/33) 
(2/341 
(2/35) 
(2/36) 
( 
29 . How long ago were you diagnosed as HIV positive? 
0 Less than a month 
0 One to six months 
0 More than six months. but less than a year 
30. How do you think you got your HIV lnfection? 
Please check all that apply 
0 Injection (IV) drug use 
0 Heterosexual contact 
0 Homosexual contact 
0 Blood transfusion 
O Other: 
0 1 to 2 years 
0 3 to 4 years 
0 5 years or more 
31. What was your T cell count (CD4 count) the last time you were tested? 
0 Greater than 500 0 201-500 Q 50-200 0 Less than 50 
.... 
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12/37) 
12/38-42) 
(2/43 -62) 
(2/63) 
( 
SECTION II 
MEDICATION HISTORY 
WHICH OF TiiE FOLLOWING MEDICATIONS ARE YOU TAKING NOW? 
- PLEASE CHECK ALL THAT APPLY: 
0 Indlnavir (Crlx1van®) 
(2/64 -77) 
0 AZT (RetroviI@. zldovudlne) 
0 DDI (Vldex®, dldanoslne) 
0 DDC (Hlvid®. zalcltablne) 
0 D4T (Zerit®, stavudlne) 
D Trimethoprirn or Sulfamethoxazole (Bactrlm®. Septra®) 
D Clartthromycln (Bl.axin®) 
0 3TC (Eplvir@, lam1vudine) 
0 Saqulnavir (Invirase®) 
0 Ritonavir (Norvir®) 
D Dapsone 
D Fluconazole (Difiucan®) 
D Itraconazole (Sporanox®) 
D Rlfabutin (Mycobutin@) 
0 Other: ~~~~~~~~~~~~~~ 
;. 
We would like to ask you about each medicine that you are currently taking. Please fill out 
the following 2 page medicationformfor each medicine that you checked on the above list. 
If you are currently taking 1 medication. fill out 2 po.ges. 
If you are currently taking 2 medications . .fill out 4 pages. 
If you are currently taking 3 medications. fill out 6 pages. 
If you are currently taking more than 3 medications. please fill out 6 pages and additional 
po.ges in the Supplement at the end of this questionnaire. 
Pease go to page 12 after you have filled out these medication forms • . 
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( MEDICATION # 1 
MEDICINE NAME. _____ ___________ _ 
L Titis medicine Is for: 
0 HIV Infection 
2. 
0 To treat or prevent PCP (Pneumocystis carinii pneumonia) 
0 To treat or prevent MAI (Mycobacterium avium complex) Infection 
0 To treat or prevent fungal Infections (Candida or ·thrush·) 
0 Other: 
--------------0 Don'tlmow 
How often do you take this medicine? 
0 Two times a week 
0 Three times a week 
0 Every other day 
D Once a day 
D Two times a day 
0 Three times a day 
0 Four times a day 
0 Five times a day 
D Other:---------
'· 
: . ·,"; 
(J/1 -20) 
(J/21) 
(J/22-41) 
(J/42-50) 
(J/51-70) 
3. How long have you been taking this medication? IJ/711 
Less than 1 month __ 6 months to 1 year 
1 to 3 months __ 1 to 2 years 
4 to 6 months __ more than 2 years 
4. During the last 3 months, have you ever stopped taking this medication because you 
felt better'? (J/nl 
DYES 0 NO 
5. During the last 3 months, have you ever stopped taking this medication because you felt 
worse? . (J/73) 
DYES 0 NO 
6. During the last 3 months. have you ever forgotten to take this medication? (3/74) 
DYES 0 NO 
7. During the last 3 months. have you at times been careless about taking this medication? (3/751 
0 YES 0 NO 
8. During the last 3 months. have you ever taken less of this medlcL•e than your doctor 
prescribed because you felt better? (J/76l 
0 YES 0 NO 
9. During the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt worse? (J/771 
0 YES 0 NO 
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( 
10 . Since you began taking this medication. have you ever purposely: 
al taken more of the medicine than your physician prescribed? 
bl taken less of the medicine than your physician prescribed? 
cl discontinued or stopped taking your medication? 
~. 
YES 
0 
0 
0 
NO 
0 
0 
0 
(3/78) 
(3/79) 
(3/801 
11. a) How many times have you discontinued your medication for more tha11.3 days? (4/1 · 21 
bl What were your reasons for discontinuing your medication? 
(Please check all that apply} 
0 My doctor recommended it 
0 Too mapy side effects 
0 I didn•t want to be reminded of my i4ness 
0 Probl~ with insurance coverage 
0 I didn•t think it was working 
0 Other.----------
(4/3-8) 
(4/9-281 
12. Sometimes it ls difficult to take prescribed medicine all the time. DurinJ! the past week. how 
many tlmes did you miss a dose of M~DICATION 1? (4/29-301 
13. During the past month, about how many times did you miss a dose of MEDICATION l? 
: (4/31-321 
?.. 
14. During the past three months. about how many times did you miss a dose MEDICATION l? 
(4/33-341 
15. Please check any side effect(s) you are having that you believe are caused by this medicine: 
(4/35-501 
0 nausea 
0 di=iness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: · 
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. 0 sbortness of breath 
0 muscle aches 
0 fatigue 
0 tingling in hands/feet 
0 numbness in hands/feet 
63 
0 
0 
0 
B 
headaches 
anxiety I worry 
depression 
rash 
·sensitivity to sun 
(4/Sl-701 
( 
MEDICATION #2 
MEDICINE NAME _____________ _ 
L Thls medicine ls for: 
0 HIV lnfectlon 
0 To treat or prevent PCP (Pnewnocystis carinll pneumonia) 
0 To treat or prevent MAI (Mycobacterlum avlum complex) Infection 
0 To treat or prevent fungal infections (Condida or ·thrush·) 
D Othd. . 
0 Don't know 
2. How often do you take this m~diclne? 
0 Two times a week 
0 Three times a week 
D Every other day 
D Once a day 
0 Two times a day 
0 Three times a day 
0 Four times a day 
0 Five times a day 
D Other:---------
3. How long have you been taking this medication? 
Less than 1 month __ 6 months· to 1 year 
1 to 3 months __ 1 to 2 years 
4 to 6 months __ more than 2 years 
4. During the last 3 months, have you ever stopped taking this medication because you 
felt better? 
DYES D NO 
(5/1-20) 
(5/21) 
(5/22-41) 
(5/42-50) 
(5/51-701 
(5/71) 
(5/72) 
5. During the last 3 months, have you ever stopped taking this medication because you felt 
worse? (5/731 
DYES D NO 
6. During the last 3 months, have you ever forgotten to take this medication? (5/741 
DYES D NO 
7. Dwing the last 3 months, have you at tima. &Jeen cnrd~s about"taking this medication? (5/75) 
DYES D NO 
8. During the last 3 months, ·have you ever taken less of this medicine than your doctor 
prescribed because you felt better? (5/761 
DYES D NO 
9. Dwing the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt worse? (5/771 
DYES D NO 
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10. Since you began taking this medication. have you ever purposely: 
a) taken more of the medicine than your physician prescribed? 
bl taken less of the medicine than your physician prescribed? 
c) discontinu·ed or stopped taking your medication? 
~. 
YES 
0 
0 
0 
NO 
0 
0 
0 
(5/78) 
(5/79) 
(5/80) 
11. a) How many times have you discontinued your medication for more than 3. days? 1s11-21 
b) What were your reasons for discontinuing your medication? (6/3·8l 
Please check all that apply 
0 My doctor recommended It 
0 Too many side effects ' 
0 I did~·t want to"be reminded ofmy;illness 
D Problems with Insurance coverage 
0 I didn•t.think it was working 
D Other: (6/9·281 
12. Sometimes lt ls difficult to take prescribed medicine all the tune. During the past week. how 
m.any times did' you ~·a dose ofMI;:DICATION 2? cs;20..:ia1 
13. During the past month, about how many times did ·you miss a dose of MEDICATION 2? 
(6/31·32) 
. ~ 
14. During the past three months, about how m.any times did you miss a dose MEDICATION 2? 
(6/33·34) 
15. Please check any side effect(s) you are having that you believe are caused by this medicine: 
(4/35·50) 
Onausea 
0dizzlness 
Ovomiting 
Oabdominal pain 
0diarrhea 
Oother. 
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0 shortness of breath 
0 muscle aches 
Oraugue 
0 tingling in hands/feet 
Onumbness in hands/feet 
65 
0 headaches 
0 anxiety /worry 
0 depression 
. D rash 
0 sensitivity to sun 
(6/51-70) 
MEDICATION #3 
MEDICINE NAME _____________ _ 
L 'This medicine Is for. 
0 Hrv Infection 
2. 
0 To treat or prevent PCP (Pneumocystis catinii pneumonia) 
0 To treat or prevent MAI (Mycobactertum avlum complex) Infection 
0 To treat or prevent fungal infections (Candida or ·thrush·) 
0 Other. . . 
0 Don't know ' 
How often do you take this medicine? 
0 Two times a week 
0 Three times a week 
0 Every other day 
0 Once a day 
0 Two times a day 
0 Three times a day 
0 Four times a day 
0 Five times a day 
0 Other.------ __ _ 
, i 
;. 
3. How long have you been taking this medication? 
Less than 1 month __ 6 months to 1 year 
1 to 3 months __ 1 to 2 years 
4 to 6 months __ more than 2 years 
4_ During the last 3 months. have you ever stopped taking this medication because you 
felt better? 
0 YES 0 NO 
(7/1 -20) 
(7/211 
(7 /22-41) 
(7/42-50) 
(7/Sl-70) 
(7/71} 
C7tm 
5. During the last 3'fnonths;"havc-you .. ever-stoppcd taklrig this medication because you felt 
worse? . (7 /7'Jl 
0 YES 0 NO 
6. During the last 3 months, have you ever forgotten to take this_ medication? 
0 YES 0 NO 
(7/74) 
7. During the last 3 montrs, have you at times been careless about' taking this medication? 1111s1 
0 YES 0 NO 
8. During the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt better? 11 /761 
0 YES 0 NO 
9. During the last 3 months, have you· ever taken less of this medicine than your doctor 
prescribed because you felt worse? 111n1 
0 YES 0 NO 
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10. Since you began taking this medication. have you ever purposely: 
YES 
a) taken more of the medicine than your physician prescribed? 0 
b) taken less of the medicine than your physician prescribed? 0 
c) discontinued or stopped taking your medication? 0 
~. 
NO 
0 
0 
0 
(7/76) 
(7/79) 
(7/60) 
l l. a) How many times have you discon~irmed your medication for more than 3 days? (6/ 1-21 
bl What were your reasons for discontinuing your medication? (6/3·61 
Please check all that apply 
0 My doctor recommend~d it 
0 Too many side effects ' ; 
0 I didn't want to be reminded ~f my l_llness 
0 Problems with insurance coverage · 
0 I didn't Ulink il was working 
0 Other. (8/9·"261 
12. Sometimes it is difficult to take prescribed medicine all the time. Durine the past week, how 
many times did you miss a dose of ~DICATION 3? (8/29-301 
13. During the past month, about how many times did you miss a dose of MEDICATION 3? 
. (8/31-32) 
';j. 
14. During the past three months, about how many times did you miss a dose MEDICATION 3? 
(8/33·34) 
15. Please check any side effect(s) you are having that you believe are caused by this medicine: 
(8/35·501 
Onausea 
0 dlzi:iness· · 
Ovomiting 
Oabdominal pain 
0diarrhea 
Oother: 
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0 shortness of breath 
Dmusclc aches 
Oraugue 
0 tingling in hands/feet 
0 numbness in hands/feet 
~· i 
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0 headaches 
0 anxiety /worry 
0 depression 
0 rash 
' 0 sensitivity to sun 
(8/51-701 
Next. we would like to ask about your attitudes toward taking each of three different kinds 
of medications. Please fill out each of the following sections ONLY if you have taken or are 
currentht taking any of the medications listed in each section. 
SECTION HI: ANTIVIRAL M£DICATIONS ...••.••. .Please go to page 13 • 
[AZT (Retrooir®, 71dooudine). DDI (Vldex®. didanoslne), DDC (Hioid®. zalcitabine). 
D4T (Zerit®. stavudine). or 3TC (Epioir@. lamioudineJ/ 
SECTION IV: ANI"I·INFECTIVE MEDIC4TIONS ••••••••• .Please go to page 21. 
(Trimethoprim or Sulf amethoxaz.ole (Bactrim®. 8ept:r:a®.J. Clarithromycin {Biaxin®). 
Ftuconazole (Dijlucan®), Itraconazole (Sporanox@). or Rifabutin (Mycobutln®)} 
. . .. . . . .. . . 
SECI:rON V: PROT.EASE INHIBITORS ••••••••• .Please go to page 29 • 
[Saqulnaoir (Inoirase®). Rit6naoir (Noroir@). or Indinaoir (Crixioan®)J 
Please go to page ~3 after you have completed these medication sections. $ 
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SECTION III 
ANTIVlRAL MEDICATIONS 
REMINDER: FILL orrr THIS SECTION IF YOU HAVE EVER TAKEN ANY OF THESE ANTIVIRAL 
MEDICATIONS: AZT (Retrovir®, zidovudine), DDI (Videx®, didanos ine), DDC (Hivid®, 
zalcitabine), D4T (Zerit®, stavudine), or 3TC (Epivir®, lamivudine). I[ not, skip to page 24. 
If you are taJcing more than one antioiral medication N.OW. please answer these 
questions for the medicine that Ls most d!JT1CUltfor you to taJce. andfill in the 
name of that medicine here ____ ~--------------
If you have discontinued your antioiral medication. please answer these ques· 
tions for the medicine Chat you took: most recently. andjlU in the name of that 
medicine here ___ ·----------------
'· i 
(9/1 · 20) 
(9/21-401 
Taking medications as directed (the prescribed amount ~en at the right time) is not alway~ easy. 
At one time or another most_ people simply forget to take a dose of their medication. and sometimes 
people discontinue taking their medications for a while. The following is a list of possible advan-
tages and disadvantages of taking antiviral medications as directed. 
For each numbered statement, please mark one box with an -x_-- to race HOW IMPORTANT 
Chat statement is to you when you are thinking about whether to taJce your antioiral 
medication as directed. 
l!:XTREMELY IMPORTANT 5 
.Y£RY ir.:N>RTANT 4 
MODERATELY J:MPORTM"T 3 
2. Taking my antiviral medication as directed may delay some 
symptoms of lilV infection. 
4. Taking too many medications may not be good for my health. 
6. Taking all of my antiviral medication as directed is too expensive. 
8 . Taking my antiviral medication as directed may make up for my 
unheal thy h abits . 
, J 
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0 
0 
0 
0 
0 
0 
0 
0 
0 0 
0 D 
D D 
D D 
D 0 
D D 
0 0 
D 0 
0 
D 
D 
D 
0 
0 
0 
D 
' 
0 
D 
D 
0 
0 
0 
0 
D 
(9/411 
(9/421 
(9/431 
(9/44) 
(9/451 
(9/46) 
(9/47) 
(9/48) 
( 
EX"ntEMELY IMPORTANT S 
VERY IMPORTANT 4 
SLIGHTLY IMPORTANT 2 
NOT IMPORTANT l 
D D D 0 0 (9/49) 
10. When I'm away from home or on vacation. taking my antiviral 
medication as directed ls dlfficulL 
12. Taking my'antivlral medication as directed causes t~o -many 
annoying side effects. · 
14. I worry that taking all the doses that are prescribed might not be 
good for me. 
16. I worry that the antiviral mediration is doing more harm than 
good. 
18. It may be hard on my system. if J take my antiviral medication 
as directed. 
D 
0 
er 
0 
0 
D 
D 
0 
0 
D 
D D 
0 0 
D D 
D D 
0 0 
D 0 
D 0 
D 0 
0 0 
D D 
0 0 (9/50) 
D D (9/51) 
D 0 (9/52) ~ 
D D (9/53) 
D D (9/54) 
D D (9/55) 
D ·0 (9/561 
D D (9/57) 
D D (9/58) 
D D (9/59) 
20. Taking my antiviral medication as directed will help me feel better. 0 0 0 0 0 (9/601 
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Sometlmes people take thelr medleatlons as directed for a while, and then stop talclng them 
for a whlle. 
- The following 2 quescions are about how you are Lalcing your antiuiral medication RIGIIT NOW. 
21. Do you consistently take your antiviral medlcaUon as dl•eeted? t·as c1ir~cted· ·means taking 
your medication at the right time and taklng the prescribed amount) · (9/61·801 
a. No. I do not. and I am not considering taking my antiviral medlcatlon as dlrected. 
b. No. I do not. but I am considering taking my antiviral medication as directed. 
c. No. I do not. but I am planning to start taking my antiviral medication as directed 
within the next month. 
__ d. Yes. I consistently take my antiviral medlcatlon as directed. 
. . 
~. . 
+- 22. How long have you been takingyour'-al)Uviral mcdlcatlon as directed? 0011) 
a. 0-3 months 
b. 4-6 months 
_ ._ c. 6-12 months 
d. more than 12 months 
Now here are some situations that might affect whether you take your antiviral medication 
for HIV infection as directed. 
For each situation. please mark one box wWt an ·x- to mte HOW TEMPTED you would be to skip your 
antiviral medication or take a dose which is d.iff erentfrom the one prescribed. · 
EXTREMELY TEMPTED 5 
VERY TEMPTED 4 "<? 
MODERATELY TEMPTED 3 
SUGHTI.Y TEMPTED 2 
1 
0 0 0 0 0 . (10/2) 
24. When you are anxious about slde effects. (10/31 
UW4•~9W»IM$1iM•ctn11g 0 0 0 0 (io/4) 
26. When you wonder whether you really need your medication. 0 0 0 0 0 (10/SJ 
0 0 0 0 (10/61 
28. When you experience minor side eITccts. 0 0 0 0 0 (10/71 
~~-W~Jit"&~'ir~ttet;1~1~•1 1~4€_~_1.K~f,~~-~-i, 0 0 0 0 0 110101 ~t?~&lli1k¥  - l~-a¥Jt<\.,.,_..,Jif{ 
30. When your doctor doesn't seem Interested ln whether you take 0 0 0 0 0 · 00101 
your medication. 
32. When side effects are annoying. 
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·: 0 0 0 0 0 (10/101 
0 0 0 0 0 (10/111 
EX'IREMELY n::tdl'TED 5 
VERY n::MPTED 4 
MODERATELY TEMPTED 3 
SUGHn.T n::MPTED 2 
34. When your medical condition doesn't seem that bad. 
36. When lt seems too complex to keep track of all your medlcatlons. 
38. When your doctor doesn't explain why you need to ~e your 
medicatlon. 
1 
0 
0 
0 
D 
D 
D 
0 0 
0 0 
0 0 
D 0 
0 0 
0 0 
0 0 (I0/12) 
0 0 (10/13) 
0 0 (10/14) 
0 0 (10/15) 
0 0 (10/16) 
0 0 (I0/171 
l.\~4Mt@iMii,lfJiti&US~.iYM!f 1101181 
40. When you aren't sure lf the medicine ls really helping you. (I0/ 191 
42. When you don't understand why you need your medication. 
44. When your family or friends don't seem concerned enough 
about your condltlon. 
-46. When your family or friends don't seem Interested in whether 
you take your medication. 
D 0 0 0 .D 1101201 
0 0 0 0 0 (10/21) 
D 0 0 0 0 uo1231 
0 0 0 .D 0 1101241 
D 0 0 0 0 1101251 
0 0 0 0 0 (10/26) 
· 48. When your Insurance doesn't cover the cost of your medication. , 0 0 0 0 0 001211 
0 D 0 D 0 1101281 
50. When you worry that taking too many medications might be bad er 0 0 0 0 (10/29) 
for your health. 
52. When you worry that the chemicals In the medication might 
harm or hurt your body. 
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0 0 0 0 0 (10/30) 
0 0 0 0 0 (10/31) 
( The following statements represent some thoughts and experiences that people have when 
they arc taking antiviral mcdlcations on a regular basis. Think about your thoughts and 
experiences during the past month . 
.... For each nwnbered statement. please mark one box with an ·x- to best describe HOW OFTEN that 
thought occurs or has occurredfor you during the past month. 
VERY OFTEN 5 
OFTEN 4 
OCCASIONAJ.LY 3 
RARELY 2 
0 0 0 D D 1101321 
54. I call my health care provider lf I have qucstioris about taking my 0 0 0 0 0 (10/33f 
antiviral medications. · 
0 D D D D 001341 
56. I reward myself when I take my anti~ medications as direct~d. 0 0 0 0 0 (l0/351 
0 o · D D D 11013s1 
58. When I am tempted to skip a dose of my antiviral medication. 0 0 0 0 0 00/371 
I remind myself about the importance of staying on schedule. 
60. I feel good about myself when I remember to take my antiviral 
medications as directed. 
62. I think that taking my antiviral medications as directed may 
provide knowledge to help others who have HIV infection. 
0 0 0 0 0 (10/38) 
D D D D 0 . 0013~1 
0 0 D 0 0 001401 
0 0 D 0 0 0014u 
D 0 D 0 0 001421 
64. When taking my antiviral medications feels like a hassle. I remind 0 0 0 0 0 (l0/431 
myself of all the benefits of continuing to take them regularly. 
66. When I'm unable to take my antiviral medications as directed. 
rm disappointed in mysclC 
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0 D D D 0 oo/44) 
0 0 0 0 0 (10/451 
( 
VERY OF"IEN S 
OFTEN .( 
OCCASIONALLY 3 
RARELY 2 
68. I think that ta.king my antiviral medications as directed will help 
my family and friends by giving them hope. 
' ; 
70. I talk to my health care provider before changing the way I. take 
my antiviral medications. .: 
72. I build taking my antiviral medications into my schedule. 
74. When I am on vacation or away from home. I make special efforts 
to continue taking my antiviral medications as directed. 
76. I ·get upset with myself when I skip my antiviral medications. 
78. When I plan my day. ~ make sure to include taking my antiviral 
medications. 
80. When it Is dlfficuit. fo take my ant~viral medications as .~ilrected. 
I remind myself that others. are counting on me.· 
82. I think that I am making a contribution to scientific knowledge 
about HIV by taking my antiviral medications as directed. 
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D D D D D (I0/46) 
D 0 D D D {I0/•7) 
D D D D D (I0/48) 
0 0 D 0 0 (I0/49) 
D D D D D (I0/501 
D 0 D D D (10/51) 
D 0 D D D {10/52) 
0 0 D D (J (10/53! 
., 
D D D D 0 (I0/54) 
D D 0 D D (10/SS) 
0 0 D D D (10/56) 
D 0 D D D (l0/57) 
D D D 0 0 (10/58) 
DDoqo (I0/59) 
DODOO 
DODOO 
DODOO 
(10/60) 
(10/61) 
(10/62) 
VERY OF"TEN 5 
OF"TEN 4 
OCCASIONALLY 3 
RARELY 2 
85. Emotional support from others helps me take my antiviral 
medications as dlrected. 
NEVER 
0 0 0 0 D 1101631 
D D D D D - 1101541 
D 0 0 D D 110165) 
87. I try to take my antiviral medications at the same time and place 0 ·O D ·o D 110/66) 
so that I won"t forget. · 
89. I use determination to help me stick to my regular 
medication-taking schedule. 
91. I tell myself and others that I will take my antiviral medications 
as directed. 
93. I have someone I can rely ·on to hclp me with my ·~mtiviral 
medication schedule. 
95. I avoid situations that make it difficult for me to remember to 
take my antiviral medications. 
97. I feel more responsible when lam taking my antiviral 
medications as directed. 
99 . I regularly ch eck m y s upply of pills . 
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D 0 D 0 .o · 00167) 
D D 0 0 0 1101681 
0 0 0 D 0 001s91 
( • 
0 D D 0 0 11ono1 
D D D D D 11on11 
0 D D D 0 1101i:21 
OOOOOoom1 
0 0 0 D 0 11on41 
0 0 D D 0 (lO/iSJ 
0 0 0 D 0 oot7GJ 
0 0 0 0 0 (I0/77) 
0 D D D 0 11017a1 
( 
VERY OFTEN :; 
OFTEN 4 
OCCASIONALLY 3 
RARELY 2 
10 l. I feel that my health care provider really hel'ps me take my 
antiviral medications as directed. 
103. I f~l that I've earned my health care provider's approval when 
I take my antiviral medications as directed. 
· .. 
105. When I get depressed, I make special efforts to continue 
taking my antiviral medications as directed. 
107. When I think of the times when I didn't care about taking 
'· · my antiviral medications. I feel angry.with myself.:· 
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0 
0 
0 
0 
0 
0 
0 
0 
.. o 
0 
0 
.. o 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
·o 
0 
0 
11 
u 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
D 
0 
•. 
·o 
0 
.o 
D 
0 
(I0/79) 
(10/80) 
01/11 
(l l/2) 
(l t/~I 
(l l/4) 
(11/5) 
(11/6) 
(11/7) 
SECTION IV 
ANTI-INFECTIVE MEDICATIONS 
REMINDER: FILL OUT THIS SECTION IF YOU HAVE EVER TAIIBN ANY OF THESE MEDICilVES 
TO HELP PREVENT PNEUMONIA OR INFECTION: 
Trimethoprim or Sulf amethoxazole (Bactrim@. Septra®,), Clarithromycin (Biaxin@). 
Fluconazole (Diflucan®), Itraconazole (Sporanox®). or Rif abutin (Mycobutin®). 
I[ not. skip to page 34 . 
...... if you arc taking more than one anti-irifective medication NOW. please answer these questions 
for the medicine that is most d!fficultfor you to take. andfiU in the name of that medicine here 
(11/8-27) 
-if you have discontinued your anti-infective medl.cation. please'an.Swer these questions 
for the medicine that you took most recently, apdf..U u1 the name of that medicine here 
(11/28-471 
Taking medications as directed (the prescribed ~ount taken.at .the tight time) is not always eas)'. 
At one time or another most people simply f~rget to take a . dose of their medication. and so~etlmes 
people discontinue taking their medications for a while.. The followirlg Js a liSt of possible advan-
tage;s and disadvantages of taking anti-infective medications as directed . 
...... For each nwnbered statement. please mark <>ne ~ l}Jit1t an ·r to rate HOW IMPORTANT that 
statement is to you when you are thinkili.g about whether_ tO take your anti-in[ectiue medication 
as directed. 
EXTRE~Y IMPORTANT -i_S 
VERT IMPORTANT 4 
MODERATELY IMPORTANT 3 
SUCR'ILT IMPORTANT 2 
NOT IMPORTANT 1 
2. Taking my anti-Infective medication as directed may delay some 
symptoms of HIV Infection. 
4. Taking too many medications may not be good for my health. 
6. Taking all of my anti-Infective medication as directed ls too 
expensive. 
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D 0 0 0 0 0114a1 · 
D 0 0 0 0 011491 
0 0 0 0 0 (11/50) 
D 0 0 0 ·0 u11511 
D D 0 0 0 1111521 
D 0 0 0 0 u 11531 
0 0 0 D 0 1111s•1 
( 
EXTREMELY IMPORTANT S 
VERT IMPORTANT 4 
MODERATELY lMPORTANT 3 
SLIGHTLY IMPORTANT 2 
NOT IMPORTANT 1 
DODOO 01/551 
9. When I take my anti-infective medication as directed. I feel more 
responsible. 
11. When I take my anti-infective medlcatlon as dlrectea.' lt·makes 
me feel depressed about having HIV infection. 
13. Taking my anti-infective medication as c,Urected will slow down 
this illness. 
15. Taking my anti-infective medication as directed gives me hope. 
17. Taking my antl~infective medication as directed may help me 
stay well longer. 
19. I worry that peuple will know that rm sick if I take my anti-
infective medication as directed. 
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0 
D 
D 
.0 
0 
0 
0 
·o 
0 
0 
0 
0 
D 0 
D 0 
D 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
D 0 (11/561 
0 0 (11/57) 
0 0 (11/581 
0 0 (ll/59) 
0 0 (ll/601 
D 0 (11/611 
!· 
~-
0 0 (11/62) 
0 0 (l l/6:1) 
0 0 (11/64). 
0 0 111/651 
0 0 (11/661 
0 0 (11/67) . 
Somctlrocs people take their medications as directed for a while. and thca stop tnklng them 
for a while . 
.... ThefoUowing 2 questions are about how you are caking your anti-infecLive medication RIGHT 
NOW. 
21. Do you consistently take your anti-infective medication as directed? c-as directed• means· taking 
your medication at the right time and taking the prescrib~d amount) (I t/681 
a . No. I do not. and I am not considering taking my anU-lnfecUve medication as directed. 
b. No. I do not. but I am considering taking my antl-lnfectlve medlcatlon ~s directed. 
c. No. I do not. but I am planning to ~tart taking my anti-Infective medication as 
directed within the next month. 
d. Yes. I consistently take my anti-infective medication as directed. 
Tfyes, 
- 22. How long have you been taking your anti-Infective medication as directed? (l l/691 
. ~ 
a. 0-3 months 
b. 4-6 months 
c. 6-12 months 
d. more than 12 months 
Now here are some situations that might affect whether you take your anti-infective a:ar:dlcation for 
HIV Infection as directed. 
- For each situation. please mark one box with an ·x:- to rate HOW TEMPTED you.would. be to 
skip your anti-infective medication or take a dose which is different from the onl!presqf.be<i 
EJCTR.EMELY TEMP'i:u> 5 
MODERATELY TEMPTED 3 
2 
NOT TEMP'IED 1 
D·O 
· 2·4. When you· are anxious about side eITects. 
. ··. 
DO 
~~Wf$~)31!fl-~Q~l!ff1Lf!e5- D 0 
26. When you wonder whether you really need your medication. DO 
Df»l1jlj0jftil@WA--fl\-fl D 0 
28. When you experience minor side eITects. D 0 
30. When your doctor doesn•t seem Interested In whether you take 
your medication. 
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0 (ll/701 
(l l/711 
(tl/nl 
(11/731 
\11/741 
(11/751 
(11/761 
!11/n) 
EXTREMELY TEMPTED S 
VERY TEMPTED 4 
MODERATELY TEMPTED :I 
SUGHTI..Y TEMP'TED 2 
32. When side effects are annoying. 
34. When your medical condition doesn't seem that bad. 
36. When lt seems too complex: to keep track of all your~edications. 
38. When your doctor doesn't explain why you need to take your 
medication. 
40. When you aren't sure if the medicine is really helptne you. 
42. When you don·t understand why you need your medication. 
44. When your family or friends dont seem concerned enough 
about your condition. 
_,.RltM~W&bMuiMti@UtK~ 
46. When your family or friends don't seem Interested in whether· 
you take your medication. 
48. When your Insurance doesn't cover the cost of your medication. 
50. When you worry that taking too many medications might be bad 
for your health. 
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0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
D D 
.D 0 
D D 
0 D 
0 0 
D 0 
D D 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
·o 
D 
0 
0 
0 
0 
0 
0 
D. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
D 
0 
0 
0 
0 
D 
0 
0 
0 
0 
0 
.o 
0 
0 
.D 
0 
to 
D 
0 
D 
0 
D 
D 
111/78) 
111/79) 
111/80) 
112/IJ 
112/2) 
(12/:JJ 
112/4) 
112/SJ 
(12/6) 
112/7) 
(12/8) 
(12/9) 
112/10) 
(12/1 IJ 
(12/12) 
(12/13) 
(12/ 14) 
112/ISJ 
(12/16) 
112/17) 
EXTREMELY TEMPTED S 
VERY TF.MPTED 4 
MODERATELY TEMPTED 3 
SUGHTI..Y TEMPTED 2 
NOT TEMPTED 
52. When you worry that the chemicals In the me~lcatlon might 
harm or hurt your body. 
. . 
0 (12/18) 
0 ll2/l9) 
The following statements represent some thoughts and experiences that people have when 
they arc taking antl-lnfcctlvc mcdlcatlons on • regular basls_ Thlnk about your thoughts and 
experiences during the past month . 
.,._ For ·each numbered statement. please mark one.~ with art ·x:- w· best ·describe HOW OFTEN th.at 
thought occurs or has occur:redfor you during the past month. 
VERY OFTEN 
OFTEN 4 
OCCASlONALLY. 3 
· RARELY 
NEVER 
54. 1 call my health care provider if l have questions about taking· 
my anti-infective medications. 
56. 1 reward myself when 1 take my anti-infective medications · 
as directed. 
58. When 1 am tempted to skip a dose of my antl-irirectt~c medication. 
1 remind myself about the importance of staying on schedule. 
60. 1 feel good about myself when I remember to take my 
anti-infective medications as directed. 
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0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 ·o 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
5 
CJ (12/20) 
0 (12/21) 
0 (12/22) 
0 (12/23) 
0 (12/24) 
0 (12/25) 
0 (12/26) 
0 (12/271 
0 (12/281 
VERY OFTEN S 
OF"reN 4 
OCCASIONALLY 3 
RARELY 2 
63. I do something special for myself when I take ~y anti-infective 
medications as directed. 
0 0 D D D 021291 
0 0 ·O 0 D 021301 
0 0 0 0 D u21311 
65. ltellmyselfthatfollowin'ga ·regularschedulewlllhelp .metakemy 0 0 0 0 D (12/321 
anti-infective medications as directed.. · " . 
67. I get upset when I hear about people like me who stop taking 
their anti-infective medications. 
69. I ask my health care provider for infor.mation about my 
anti-infective medications. 
71. Someone close to me reminds me t:o take my anti-infective 
medications as directed. 
73. I use a pill organizer or timer to help me take my anti-infective · 
medications as directed. 
75. I encourage myself to stick to my regular medication schedule. 
77. I feel that when I take my anti-infective medications as directed. 
I am a good role model for others. 
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0 0 0 0 D 1121331 
0 0 D 0 0 1121341 
0 0 D 0 D 1121351 
i_. 
ooood (12/36) 
DODOO (12/37) 
DODOO (12/38) 
DODOO (12/39) 
0 0 .D 0 0 1121401 
'O 0 D 0 0 u21411 
0 0 D 0 0 u21421 
0 0 0 _O 0 u2t43) 
0 0 D 0 D u214c1 
VERY OFTEN 5 
OFTEN 4 
OCCASIONALLY 3 
RARELY 2 
79. l use everyday events like brushing my teeth or when my alarm 
clock goes olT to remind me to take my antl-~nfectlve medications 
on time. 
81. l stick to my plan for taking my antl-lnfcctlve medlcitl.ons as 
directed . 
.. . .. ..  
83. l think about the benefits of taking mY: ant1-lnfcctive medications. 
85. Emotional support from others helps me take my anti-Infective 
medications as directed. 
87. l try to take my anti-Infective medications at the same time and 
place so that l won"t forget. 
89. l use determination to help me stick to my regular medicatlon-
taking schedule. 
91. l tell myself and others that l will take my anti-infective 
medications as directed. 
93. I have someone I can rely on to help me with my anli-infcclivc 
medication schedule. 
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0 0 0 0 0 (12/45) 
DODOO (12/46) 
0 0 0 0 0 (12/47) 
0 0 0 0 0 (12/481: 
0 0 0 0 0 (12/49) 
0 0 0 0 0 (12/&0l 
0 0 0 0 ·o (12/51) 
0 0 0 0 b (12/52) 
0 0 0 0 0 (12/53) 
0 0 0 0 0 (12/54) 
0 0 0 0 0 (12/55) 
0 0 0 0 0 (12/56) 
0 0 0 0 0 (12/57) 
0 0 0 0 0 (12/58) 
0 0 0 0 0 (12/59) 
0 0 DO 0 (12/GOl 
VERY OFTEN S 
OFTEN 4 
OCCASIONALLY 3 
RARELY 2 
95. I avoid situations that make it difficult for me to remember to 
take my antl-lnfective medications. 
97. I feel more responsible when I am taking my antl-lnfectlve 
medications as directed. 
99. I regularly check my supply· of pills. . 
101. I feel that my health care provider really helps me take my 
anti-infective medications as directed. 
103. I feel that I've earned my health care provider·s approval when 
I take my antHnfectlve medications as directed. 
lOq, When I get depressed. I make special efforts to continue taking 
my anti-infective medications as directed. 
107. When I think of the times when I didn"t care about taking my 
anti-infective medications. I feel angry with myself. 
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0 0 0 0 0 (12/61) 
0 0 0 0 0 (12/62) 
. q 0 0 . 0 0 (12/63) 
0 n 0 0 0 (12/&4) 
0 0 0 0 0 (12/65) 
0 0 ·o 0 0 (12/66) 
0 0 0 0 0 (12/67) 
~ 
0 0 0 0 0 (12/68) 
0 0 0 0 0 (12/69) 
D 0 0 0 0 (12/70) 
0 0 0 0 0 (12/71) 
0 D 0 0 0 (12/72) 
0 0 0 0 0 (12/731 
0 0 OD 0 u2n41 
0 0 0 0 0 u2ns1 
SECTION V 
PROTEASE INHIBITOR MEDICATIONS 
REMINDER: FILL OUT THIS SECTION IF YOU HAVE EVER TAKEN ANY OF THESE PROTEASE 
fNffIBITOR MEDICATIONS: Saquinauir (Inuirase®). Ritonauir (Norvir®). or Indinauir 
(Crixiuan®). If not, skip to page 39. 
- If you are taking more than one protease lnhlbitor medica.ti.on NOW. please answer these 
questions for the medicine that is most dfjfu;ultfor you to take. and fill in the name of that 
medicine here (1311 -201 
- If you have discontinued your protease inhibitor medica.ti.on. please answer these 
questions for the medicine that you took most recently. and.fiU•in the name of that medicine 
here · · (13/21-40) 
' ; 
Taking medications as directed (the prescribed amount taken at the rtght time) ls not always easy. 
N ~me time or another most people simply forget to take:a <lose of tpeir medication. and s9me~es 
people discontinue taking their medications for a while: The following ls a list of possible advantages 
and disadvantages of tak1ng orotease inhibitor medications as directed. 
- For each numbered statement. please mark one box with an -x: to rate HOW .IMPORTANT th.at 
statement is to you when you are thinking about whether to take your prote.ase inhibitor 
medication as directed. 
EXTREMELY IMPORTANT 5 
VERY IMPORTANT 4 
~ 
MODERATELY IMPORTANT 3 
SLlCKil.Y IMPORTANT 2 
NOT IMPORTANT l 
0 0 0 0 0 (13/41) 
2. 
4. 
6. 
8 . 
Taking. my protease inhibitor medication as directed may delay 
some symptoms of HIV infection. 
Taking too many medications may not be good for my health. 
Taking all of my protease Inhibitor medication as directed ls 
too expensive. 
Taking my protease Inhibitor medication as directed may make up 
for my unhealthy habils . 
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0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 0 (13/42) 
0 0 0 (13/43) 
0 0 D (13/44) 
0 0 ·o (13/45) 
0 0 0 (13/46) 
0 0 0 (13/47) 
D 0 D (IJ/41:!1 
r 
I ElCIREMELY IMPORTANT S 
VERY IMPORTANT 4 
MODERATELY IMPORTANT 3 
SUCltTLY IMPORTANT 2 
NOT IMPORTANT 
0 0 0 0 0 (13/49) 
10. When rm away from home or on vacation. taking my protease 
lnhlbitor medication as directed ls dlfficulL 
12. Taking my protease lnhlbitor ~edlcatlon as directed causes too 
many annoying side effects. 
14. I worry that taking all the doses that arc prescribed might not 
be good for tne. · 
16. I worry that the protease inhibitor medication ls doing more 
harm than good. · · 
18. It may be hard on my system. If I° take my protease inhibitor 
medication as directed. 
20. Taking my protease lnhlbitor mcdicatlon as directed will help 
me feel better. 
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0 
0 
0 
0 
D 
D 
0 
D 
0 
D 
0 
0 0 
0 0 
0 0 
0 0 
D 0 
D 0 
D 0 
D 0 
0 0 
0 0 
D · o 
0 0 (13/50) 
0 D (13/511 
0 D {13/52) 
D 0 (13/53) 
0 0 {13/54) 
D 0 {13/55) 
< 
~ 
0 0 (13/56) 
D 0 (13/57) 
D 0 (13/58) 
D 0 (13/59) 
D 0 (13/60) 
' 
' 
r 
Sometlmes people take their medications as directed for a while, and then stop taklng them 
for a while. 
- The following 2 questions are about how you are taking your protease inhibilor medication RIGHT 
NOW. 
21. Do you consistently take your protease inhibitor medication as directed? ("as directed" 
means taking your medication at the right time and taking. the prescribed amount) 
(13/61) 
.. . . . 
__ a. No, I do not. and I am not considering taking my protease inhibitor medication as 
directed. · 
__ b. No, I do not. but I am considering taking my protease lnhlbltor medication as directed. 
__ c. No. I do not. but I am planning to start taking my protease Inhibitor medication as 
directed within the next month. ' 
__ d. Yes. I consistently take my protease lhhlbitor medication as directed. 
, ' 
. 
22. How long have you. been taking your protease Inhibitor medication as directed? (13/62) 
a. 0-3 months 
b. 4-6 months 
c. 6-12 months 
d. more than 12 months 
Now here arc some sltuatlons that might affect whether you take your protease lnhlbitor 
medication for HIV infection as directed. 
·;,; 
- For each si.tu.ation, please mark one box with an -x: to rate HOW TEMPTED you would be to skip 
your protease inhibitor medication or take a dose which is dijferentfrom the one prescribed. 
EXTREMELY TEMPTED 5 
VERT TEMPTED 
140DERATELT TEMPTED 3 
SUGKTLT TEMPTED 2 
NOT TEMPTED 
24. When you are anxious about side effects. 
26. When you wonder whether you really need your medication. 
28. When you experience minor slde effects. 
30. When your doctor doesn't seem interested in whether you take 
your medication. 
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l 
DO 
0 0 
0 0 
D 0 
D 0 
D 0 
0 0 
0 0 
0 
0 
0 
0 
0 
0 
0 
0 
4 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
(13/63) 
(13/64) 
(13/65) 
(13/661 
(13/671 
(13/68) 
(13/69) 
(13/70) 
·;j 
( 
') 
.-
EXTREMELY TEMPTED S 
VERY TEMPTED 4 
MODERATELY TEMPTED 3 
SUGll"TLY TEMPTED :Z. 
NOT TEMl"'n:D 
32. When side effects are annoying. 
34. When your medical condltlon doesn't seem that bad. 
36. When lt seems too complex: to keep track of all your medications. 
38. When your doctor doesn't ex:plaln why you need to take your 
medication. 
40. When you aren't sure lf the medicine ls really heiplng you. 
42. When you don't understand why you need your medication. 
44. When your family or friends don't seem concerned enough about 
your condition. 
46. When your family or friends don't seem interested ln whether 
you take your medication. 
48. When your insurance doesn't cover the cost of your medication. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
D 
0 
0 
0 
0 
D 
0 
0 
0 
0 
0 
D 
0 
0 
0 
D 
D 
0 
0 
0 
D 
0 
D 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 D 
D D 
D 0 
D D 
0 D 
0 D 
0 0 
0 0 
D 0 
0 0 
0 0 
0 0 
D_ (13/711 
0 (13/721 
0 (13/731 
0 (13/741 
0 (13/751 
D (13/761 
0 (13/77) 
0 (13/781 
-0 (13/791 
.o t. (13/801 
0 (14/ll 
0 (14/2l 
0 (14/31 
0 (14~41 
0 (14/51 
0 (14/61 
D (14/71 
0 (14/8) 
D 0 D 0 0 (14/91 
50. When you worry that taking too many medications might be 
bad for your health. 
f~tf~1?Jl!~i!-~~28:~\It?i~~-l~liJ~~~~l91ts, 
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0 0 
DO 
D D 0 (14/101 
DO 0 (14/llJ 
( 
l EXTREMELY TEMPTED 
l VERY TEMPTED l MODERATELY TEMPTED 3 
lSUGllTI..T TEMPTED 2 
r NOT TEMPTED l 
s 
52. When you worry that the chemicals In the medication might 
harm or hurt your body. 
0 0 0 0 0 (14/121 
SECTION VI 
WAYS OF COPING WITH lilV 
Here are some ways that dUf erent people may cope with HIV and its treatments. There are 
no right or wrong answers. · 
- In the last month. HOW OFTEN did.you think.feel; or do each item? 
(Please circle one number for each item) l VERT OFTEN 
l OFTEN 
OCCASIOKAU.T 3 
RARELY 
In the last month, I 
--...... ~-jntlfj 
2. felt the only thing to do was wait .................................................. 
r•a.ta~•@»Ai;M1$tirn%1f.tfMM!JfAW,,.&J.iil .. tfirn.@tf# 
4. talked to someone .to find out more ...... : ............... :., ............... ~:.~ •... 
~$]Elu•mmttt:C:ifitii\Mi!ih!l+iM!-W4i*1B!Ufl,@!!ll 
6. tried not to close oCf options ........................................•................. 
8. went along with fate .................................................................... . 
lt'Mm®J#$JltmWS*!$1bYU\.wU+;,:4t..,,j!i..~4-£ .. J.ijf .•. J.4£fi 
10. tried to keep my feelings to myself ..............................•.............. :. 
ilm~til'titeinat'.1bifdtBitd.1dhiitJ.\1Mta&iMQi .. t; 
12. slept more than usual ................................................................. . 
... o · 
.f$ .. 
14. was Inspired to be creative····························-··········-·--··········· 
~ 
16. tried to get professional help ....................................................... . 
~""";"iff'~~·•WA.,_ ... Y~""=,w~,ml'·~1W'r·''I<¥~~l7-:.1~n~ngc;J!i§;gg.;ey.1ra~m:.f§P_IJlf.m~ig9,Q~Y1~.-.-.-~~~ 
18. wailed to see what would happen before acting ........................... . 
Unil.<ersi1y of lllvxlc l~lond. 0199G - ~ 
89 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 -I 
1 
1 
1 
1 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
· 4 
4. 
4 
4 
4 
4 
5 
,., 
~ 
5 (14/131 
5 (14/14) 
5 (14/15) 
5 (14/16) 
5 (1.4/17) 
5 (14/161 
5 (14/191 
5 (14/201 
5 (14/211 
5 (14/221 
5 (14/231 
5 (14/241 
5 (14/25) 
' 5 · (14/26) 
5 (14/27) 
5 (14/26) 
5 (14/291 
5 (14/JOI 
( 
l VERYOF'n:N 5 
OFTEN 4 
OCC/\SIONl\LLY 3 
rl RARELY 2 
l 2 3 4 5 (14/31) 
20. let my feelings out somehow ......................... : ............................. . l 2 3 4 5 (14/32) 
mW,®YtetoJ!t~~~tHe{!W.$1W®lh!fctfi!i~Bi~~M% l 2 3 4 5 (14/33) 
22 . . talked to someone who could do something ···················-············ l 2 3 4 5 (14/34) 
l 2 3 4 5 (14/35) 
24. took a big chance and dld something risky ··············!.··················· 1 2 3 4 5 (14/36) 
K~~tnjjRfi)la'.G$t@)BU!W4<i!A.!ME!m!4~t'hv.WOOJ.~11*-«• l 2 3 4 5 (14/37) 
26. found new faith ............ ~ .................•................. , ......................... . 1 2 3 4 5 (14/38) 
~,oV.U£dtWWMS'imooffiifit*.fftel!A!!i™MUU.Q.Qi.$J@@.t¥¥.M. 1 2 3 4 5 (14/39) 
28. changed something so things will tum out.-·-····-··········-··········· l 2 3 4 5 (14/40) 
~ak.o.t ~m!rS!~fifi~B'sM~•~t¥v-}!l@MmmaJl2.WJ11 •. M:J,f.k!lkl. l 2 3 4 5 (14/41) 
30. didn"t let it get to me: refused to think about it · ........................... . 1 2 3 4 . 5 (14/42) 
trs3t@~mMt6Iatist#tfq1$,3;tr®iifi9-12·1M!lhilD¥ftM 1 2 3 . 4 5 (14/43) 
32. kept others from knowing how bad things were .......................... . 
~J{iit'(~li'f!m?§t#1\:o\ter~~t®UQfkM~,.fi]~ 
l 2 3 4 5 (14/44) { 
1 2 3 4 5 (14/45) 
34. tal.ked to someone about how I was feeling .................................. . l 2 3 4 5 (14/46} 
W:-35.'iitCf.Q'lr@Ji~,U.t~~~..JiW#l#*Kse~.9a'-!!!L! 1 2 3 4 5 (14/47) 
36. drew on past experiences from similar situations··········-····-·-···· l 2 3 4 5 (14/481 
ft™.Gtilwf~A~:~.PWMMdWWJliiJ}~-- 1 2 3 4 5 (14/49) 
38. refused to believe it was happening ..............................••.............. 1 2 3 4 5 (14/sO) 
i{9~1j,@fh~f{QlUUai@l.LZ@i.iQi4P.1'-¥·J¥.,.•Q£t¢tm'1 1 2 3 4 5 (14/51) 
40. tried to keep my feelings from Interfering •............................. : ..... . l 2 3 . 4 5 (°14/52) 
t~~tdf§'.o'.m"«G!l!?.]lMmsWMi.uj.!ii.U4¥4i-IMl!!P••i#- l 2 3 4 5 (14/53) 
42. wished the situation would go away or be over····························: l 2 3 4 5 (14/54) 
~!faY(~arnmwn:o~\f1ninlJMM-i!ttllB 1 2 3 4 5 (14/55) 
44. prayed .................. ................................................•...................... 1 2 3 4. 5 (14/56) 
r&ifill;G1i!trul:t\~1rm:m§~f,,;wmw .... M£K¥ .. &.J.Qt.;,..:.;•~ l 2 3 4 5 (14/57) 
46. went over ln my mind what I would say or do ••............................ l 2 3 4 5 (14/58) 
--d~lmtonimm;elto}!tfit!&iMi·t- l 2 3· 4 5 (14/59) 
48. reminded myself how much worse things could be ••••••••••••••.•.••.••• ' l 2 3 4 5 (14/60) 
E-mtd.!jmmfciiW@,jit1Jiii.UJ.fa£..4MUkl!~~i 1 2 3 4 5 (14/61) 
50. treated the Illness as a challenge ...................... ..... ............... ...... . 2 3 4 5 (14/62) 
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Now here are some questions about Injection (skin popping or rv) drugs. 
Please circle or fill in the correct response for each question.. 
51. Have you ever used Injection drugs? 
0 No 
0 Yes. 
. (14/631 
- Pleasejill out the remaining questions only if you have ever used injection dn.tgs. 
52. Do you use Injection drugs now? , 
0 No. not In the past 6 months _· 1: ! . 
0 Not now. but once or twice In the past 6 months _ 
0 Yes. occasionally .-.. 
0 Yes. regularly 
If infected at all during the past 6 months. 
- 53. Puring the past 6 months. how often have you injected the following: 
NEVER 
a. Heroin by itself 0 
b. Cocaine by itself? 0 
c. Cocaine and heroin. or speedball? 0 
d. Amphetamines. such as uppers. 0 
speed. mcth. or crack? 
LESS 
TiiAN 
'IWICE 
PER 
MONTH 
0 
0 
0 
0 
2-4 
TIMES 
PER 
MOl'llli 
0 
0 
0 
0 
2 -7 
TIMES 
PER 
WEEK 
0 
0 
0 
D 
(14/641 
MORE 
1liAN 
ONCE 
PER 
DAY 
CJ 
0 
0 
0 
(14/65) 
(14/66) 
(14/67) 
(14/681 
- 54. During the past 6 months; how often did you use a brand new needle or one that you are 
sure no one else used EACH TIME you shot up? (14/69) 
0 Never 0Rarely 0 Sometimes 0 Almost always OAiways 
- 55. During the past 6 months. how many people did you share needles or works with? (14/70l 
0 None 
0 l other person 
0 2-3 different people 
0 4-10 different People 
0 More than 10 different people 
Unlue<slly of Rhode Island 0 I 99G 
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- 56. During the past 6 months. how often have: 
LESS MORE 
THAN 2-4 2·7 THAN 
'IWJ.CE TIMES Tll\tES ONCE 
PER PER PER PER 
NEVER MONTit MONTH WEEK DAY· 
a. You used needles or works after 0 0 0 0 0 
someone without cleaning? 
b. Others used needles or works after 0 0 0 0 0 
you without cleaning? 
c. You used a needle after· someone 0 D ·o D 0 
who ls HIV positlve had used lt? 
, 1 
d. You shot up ln a shooting gallery. o· q 0 0 0 
hit house or another place where ;,. 
groups of users shoot up? 
e. You shared rinSe water? D D D 0 0 
f. You shared a cooker? D D 0 D 0 
g. You shared cotton? 0 0 0 0 q 
- 57. Duling the past 6 months. where did you get needles? 
SOME of your needles 
(Answer yes or no to all) 
YES NO 
ta%£'.~reJSJ~mr~a11~ 0 0 
b. On the street? 0 D 
t~M~Q;;omf~~ D D 
d. At a drugstore? D 0 
0 0 
f. From a diabetic? 0 D 
D D 
h . From another place not D D 
mentioned? 
MOST of your needles~ 
(Check only one} 
0 
D 
D 
D 
D 
D 
D 
D 
(14/71) 
(14/721 
(14/731 
(14/741 
(14°/75) 
(14/76) 
(14/771 
(14/781 
(14/79) 
(14/80) 
(lS/_I) 
(15/2) 
(15/31 
(15/4) 
(15/S) 
- 58. During the oast 6 months. lf you haven't used a needle exchange . ..or if you had difficul-
ties getting needles from a needle exchange. how come? (IS/EH 1) 
Please check all that apply 
0 Don't know about lt 
0 Too far 
0 Open too few hours 
0 Scared of getting arrested 
0 Scared someone will see me there 
0 Other reason (please specify} c1s112-32J 
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59. Arc you pla nning to use only your own works (needles. syringes. cotton. cooker. rlnse 
waler) or a brand new needle EVERY TIME you inject within the next 6 months? If so. 
how soon? (15/331 
60. 
61. 
0 
0 
8 
0 
NO. I am not planning to start using new needles every time 
YES. within the next year 
YES. within the next 6 months 
YES. within the next month 
YES. I already use new needles every tlme 
Have you been using new needles every Ume you use IV needles? 
If so. for how long? 
D NO. I have not been uslng uslng new needles every tlme 
0 YES. for 30 days or less '· l 
0 YES. for MORE than 30 days but LESs truin 6 months 
0 YES. for MORE than 6 months but LESS llian a year 
0 YES. for MORE than a year · 
Now. how ready are you to STOP using injection drugs completely? 
O Notready 
0 Somewhat ready 
0 Ready 
0 Very Ready 
For information about needle exchange in Rhode Island. call (401} 277-2320. 
(15/34) 
(15/35) 
For informati.on on the ·Medication for The Needy-Assistance Program· at The Unioersity of Rhode 
Island. call 1-800-215-9001. 
This completes this suruey. Thank youfor your assistance with this project &for sharing 
your thoughts on mv related medications. 
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SUPPLEMENT TO SECTION II 
MEDICATION #4 
MEDICINE NAME __________ _______ _ 
L This medicine ls for: 
0 HIV infection 
2 . 
3. 
0 To treat or prevent PCP (Pneumocystis carinU pneumonia) 
0 To treat or prevent MAI (Mycobacterium avium complex) infection 
0 To treat or prevent fungal infections (Candida. or •furush·) 
0 Other.------------0 Don•tknow 
How often do you take thiS medicine? 
0 Two times a week 
0 Three tlmes a week 
0 Evexy other day 
0 Onceaday 
O . L\vo times a day 
0 Three tlmes a day 
0 Four times a day 
0 Five times a day 
D Other.---------
How long have you been taking this medication? 
Less than 1 month __ 6 months to 1 year 
1 to 3 months __ 1 to 2 years 
4 to 6 months __ more than 2 years 
(15/36-55) 
(15/56) 
(15/57-76) 
(15/77) 
(16/ l -2,0) 
4 . During the last 3 months. have you ever stopped taking this medication because you felt 
better? (16/2 IJ 
DYES D NO 
5. Duling the last 3 months. have you ever stopped taking this medication because you felt 
worse? (16/22) 
DYES D NO 
6. During the last 3 months. have you ever forgotten to take tli1s medication? (16/23) 
DYES D NO 
7 . Duling the last 3 months. have you at times been careless about taking this medlcatlon?(l6/24l 
DYES D NO 
8 . During the last 3 months. have you ever taken less of this medicine than your doctor pre-
scribed because you felt better? (16/25) 
DYES D NO 
9. During the last 3 months. have you eveF taken less of this medicine than your doctor pre-
scribed because you felt worse? (16/261 
0 YES 0 NO 
Uniucrsify of /lhodc Island. O l 99G 
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10. Since you began taking this medication. have you ever purposely: 
YES NO 
a) taken more of the medicine than your 
physician prescribed? 
0 0 (16/27) 
bl taken less of the medicine th~n your physician 
prescribed? 
0 0 (lC/!!5l 
c) discontinued or stopped taking your medication? 0 0 {16/291 
12. 
13. 
14. 
15. 
- 11.a) How many times have you discontinued your meqlcation for more 
than 3 days? 
b) What were your reasons for discontinuing your medication? 
Please check all that apply 
0 My doctor recommended it 
0 Too many side effects . 
0 I didn•t want to be reminded of my illness 
0 Problems with insurance coverage 
D I didn't think it was working D Other: . . 
{16/30-311 
(16/32·37) 
(38-57) 
Sometimes it is difficult to take prescnbed medicine all the time. During the past week, how 
many times did you miss a dose of MEDICATION 4? "· (16/58-59) 
During the past month, about how many times did you miss a dose of MEDICATION 4? 
(16/60-611 
During the past three months, about how many times did you miss a dose MEDICATION 4? 
(16/62-63) 
Please check any side cffect(s) you are having that you believe are caused by this medicine: 
(16/64-791 
D nausea 
0 dizziness 
0 vomiting . 
0 abdominal pain 
0 diarrhea 
0 other. 
0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tingling in hands/feet 
0 numbness in hands/feet 
0 headaches 
0 anxiety /worry 
0 depression 
0 'rash 
D sensitivity to sun 
{17/1·20) 
University of Rhode Island. () / 996 
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MEDICATION #5 
MEDICINE NAME _________________ _ 
l. 111.ls medicine is for: 
0 HIV infection 
0 To treat or prevent PCP (Pneumocystis carinii pneumonia) 
0 To treat or prevent MAl (Mycobacterium avium complex) infection 
0 To treat or prevent fungal infections (Candida or ·thrush·) 
0 Other:------------0 Don"t lmow 
2. How often do you take this medicine? 
D Two times a week 
D nu-ee times a week 
D Evexy other day 
D Once a day 
D Two times a day 
D Tilree times a day 
D Four times a day 
D Five times a day 
I ; 
D Other:----------
3. How long have you been taking this medication? · 
Less than l month 
l to 3 months 
4 to 6 months 
__ 6 months to l year 
__ l to 2 years 
__ more than 2 years 
(17/21-40) 
(17/41) 
(17/42-QI) 
(17/621 
(18/1-20) 
(18/211 
4. During the last 3 months. have you ever stopped taking this medication because you felt 
better? (18/221 
DYES D NO 
5. During the last 3 months. have you ever stopped taking this medication because you felt 
worse? - · (18/2JJ_ 
DYES D NO 
6. During the last 3 months. have you ever forgotten to take thl.S ~edication? (18/24} 
DYES D NO 
7. During the last 3 months. have you at times been careless about ,taking this medicatlon?(l8/251 
DYES D NO 
8. During the last 3 months. have you ever taken less of this medicine than your doctor pre-
scribed because you felt better? (18/261 
DYES D NO 
9. During the last 3 months. have you ever taken less of this medicine than your doctor pre-
scribed because you felt worse? (18/271 
DYES D NO 
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10. Since you began taking this medication. have you ever purposely: 
YES NO 
a) taken more of the medicine than your 
physician prescribed? 
0 0 (18/281 
bl taken less of the medicine than your physician 
prescribed? 
0 0 (18/291 
c) discontinued or stopped taking your medication? 0 0 (18/30) 
12. 
13. 
14. 
15. 
....... 11.a) How many times have you discontinued your medication for more 
than 3 days? . • 
b) What were your reasons for discontinuing your medication? 
Please check all that apply .. 
0 My docto.r recommended it 
0 Too many side effects 
0 I didn't want to be reminded of my illness 
0 Problems with insurance coverage 
0 I didn't think it was working 
0 Other."-----------
(18/31-32) 
(18/33-38) 
(18/39-58) 
Sometimes it is difficult to take prescribed medicine all the time. DurinJ! the past we~k, how 
many times did you miss a dose of MEDICATION 5? · (18/59-60! 
During the past month, about how many times did you miss a dose of MEDICATION 5? 
(18/61-62) 
During the past three months, about how many times did you miss a dose MEDICATION 5? 
(18/63-64) 
Please check any side effect(s) you are having that you believe are caused by this medicine: 
(18/65-80) 
0 nausea 
0 dizziness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: 
0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tingling in hands/feet 
0 numbness in hands/feet 
· 0 headaches 
0 anxiety/worry 
0 depression 
o ·rash 
0 sensitivity to sun 
(19/1-201 
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MEDICATION #6 
MEDICINE NAME _________________ _ 
L This medicine is for: 
0 HIV infection 
0 To treat or prevent PCP (Pneumocystis carinii pneWTIDnia) 
0 To treat or prevent MAI (Mycobacterium avium complex) infection 
0 To treat or prevent fungal infections (Candida or ·thrush·) 
0 Other: __ ·-----------0 Don't know 
2_ How often do you take this m~dlcine? 
0 Two times a week 
0 Three times a week 
0 Every other day 
0 Once a day 
0 Two times a day 
0 Three times a day 
0 Four times a day ·-
0 Five times a day 
0 Other:---------
3_ How long have you been taking this medication? 
Less than l month 
l to 3 months 
4 to 6 months 
__ 6 months to l year 
__ l to 2 years 
__ more than 2 years 
(19/21-40) 
(19/41) 
(19/42-61) 
(19/62) 
(20/1-20) 
(20/21) 
.( 
4_ Duling the last 3 months. have you ever stopped taking this medication because you felt 
better? 1201221 
DYES D NO 
5. Duling the last 3 months. have you ever stopped taking this medication because you felt 
worse? - (20/231 
DYES D NO 
6. During the last 3 months. have you ever forgotten to take this medication? (20/24) 
DYES D NO 
7. During the last 3 months. have you at times been careless about ,taking this medicatlon?120/2Sl 
DYES D NO 
8_ During the last 3 months. have you ever taken less of thls medicine than your doctor pre-
scribed because you felt better? 120/26) 
DYES D NO 
9. During the last 3 months, have you ever taken less of this medicine· lhan your doctor pre-
scribed because you felt worse? 12012n 
DYES D NO 
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10. Since you began taking this medication. have you ever purposely: 
a) 
b) 
c) 
YES NO 
taken more of the medicine than your 0 0 
physician prescribed? 
taken less of the medicine than your physician 0 0 
prescribed? 
discontinued or stopped taking your medication? 0 0 
~ 
...... 11.a) How many times have you discontinued your medication for more . 
than3 days? 
I 
. bl What were your reasons for discootlnuing your medication? 
Please check all that apply 
0 My doctor recommended it 
0 Too many side effects .. _ 
· 0 I didn't want to be reminded of my illness 
0 Problems with insurance coverage 
0 I didn't think it was working 
0 Other:-----------
(20/28) 
(20/29) 
(20/30) 
(20/31-32) 
(20/33-38) 
(20/39-581 
12. Sometimes it ls difficult to take prescribed medicine all the time. During the past week, how 
many times did you miss a dose of MEDICATION 6? " (20/59-601 
~ 
13. During the past month, about how many times did you miss a dose of MEDICATION 6? 
(20/61-621 
14. During the past three months, about how many times did you miss a dose MEDICATION 6? 
(20/63-64) 
15. Please check any side effect(s) y.ou are having that you believe arc caused by this medicine: 
(20/SS·BOl 
0 nausea 
0 dizziness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: 
Uniocrsity of ni.odc lslOJ\d. 01996 
0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tingling"in bands/feet 
0 numbness in hands/feet 
99 
0 headaches 
0 anxiety/worry 
0 depression 
0 rash 
0 sensitivity to sun 
(21/1·20) 
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( 1. Pl.ot of Temptation to skip Protease Inhibitors for Total. scal.e Vs Pain interfering with work in past 4 weeks 
Pl.ct of Y*QI25. Legend: A 1 obs, B 2 obs, etc. 
'{ 
40 + A A 
39 + 
38 + A 
37 + 
36 + A 
35 + A A 
34 + A 
33 + B A 
32 + 
31 + A A 
30 + A A 
29 + A A 
28 + A A 
27 + A A 
26 + A A A 
25 + 
.. 
A A 
24 + c c B 
23 + A A A 
22 + B B A 
21 + B A B 
20 + B A A 
19 + B E A 
18 + B A 
17 + A A 
16 + B A 
15 + A A 
14 + 
13 + A 
---+------------+------------+------------+------------+--
1 2 3 4 5 
INTERFERENCE W/WORK/PAST 4 WKS 
NOTE: 76 obs had missing values . 
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( 
~/' 
2 . Plot of Temptation to skip Protease Inhibitors for Total scale Vs # of days in bed in 
the past 2 weeks 
Plot of Y*QI26. Legend: A 1 obs, B = 2 obs, etc. 
y 
40 + A A 
39 + 
38 + A 
37 + 
36 + A 
35 + B 
34 + A 
33 + B A 
32 + 
31 + A A 
30 + A A 
29 + A ., I A 
28 + B 
27 + A A 
26 + A A A ;.. 
25 + A . A 
24 + D A c 
23 + A A A 
22 + c A A 
21 + D A 
20 + B A A 
19 + E B A 
18 + B A 
17 + A A 
16 + B A 
15 + A A 
14 + 
13 + A 
---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+--
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
I DAYS IN BED/PAST 2 WKS 
NOTE: 76 obs had missing values . 
IOI 
3. Plot of Temptation to skip Protease Inhibitor for Total scale Vs # of hospitalizations 
In the past year 
Plot of Y*QI27. Legend: A 1 obs, B ~ 2 obs, etc. 
y 
40 + B 
39 + 
38 + A 
37 + 
36 + A 
35 + A A 
34 + A 
33 + B A 
32 + 
31 + A 
30 + A · A 
29 + B 
28 + B 
27 + A A 
26 + c 
25 + B ~· 
24 + G A 
23 + B A 
22 + c B 
21 + E 
20 + c A 
19 + E A A A 
18 + A B 
17 + A A 
16 + c 
15 + A A 
14 + 
13 + A 
--+-------+-------+-------+-------+-------+-------+-------+-------+--
0 1 2 3 4 5 6 7 8 
t HOSPITALIZATIONS/PAST YR 
NOTE: 77 obs had missing values. 
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( 4. Plot of Temptation to skip Protease Inhibitors for Total scale Vs T cell count last 
tested 
Plot of Y*QI31. Legend: A 1 obs, B 2 obs , etc . 
y 
40 + A A 
39 + 
38 + A 
37 + 
36 + A 
35 + A A 
34 + A 
33 + A B 
32 + 
31 + · A A 
30 + B 
29 + A · A 
28 + A A 
27 + A A 
26 + A B 
25 + A A 
24 + A c c 
23 + B A 
22 + A B B 
21 + c A A 
20 + B A A 
19 + D c A 
18 + A B 
17 + B 
16 + A A A 
15 + A 
14 + 
13 + A 
---+----------------+----------------+----------------+--
1 2 3 4 
T-CELL COUNT LAST TESTED 
NOTE: 78 obs had missing values. 
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( 5. Plot of # of doses missed in the past three months Vs Pain 
interfering with work in the past 4 weeks 
40 + 
35 + 
30 + 
p 
I 
• 
M 25 + 
I 
s 
$ 
E 
D 
20 + 
D 
0 
$ 
E 
$ 
I 15 + 
3 
M 
0 
10 + 
5 + 
0 + 
A 
A 
A 
A 
A 
B 
B 
c 
L 
Plot of MISSPI*QI25. Legend: A 
A 
A 
A 
A 
A 
B 
B 
E 
A 
G 
A 
A 
A A 
A B 
A 
c 
c E 
1 obs, B 2 obs, etc. 
A 
A_ 
---+------------+------------+------------+------------+--
1 2 3 · 4 5 
INTERFERENCE W/WORK/PAST 4 WKS 
NOTE: 78 obs had missing values. 
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6. Plot of # of doses missed in the past 3 months Vs # of days in 
bed in the past 2 weeks 
p 
I 
40 + 
35 + 
30 + 
M 25 + 
I 
s 
s 
A 
E A 
D 
20 + 
D A 
0 
s 
E 
s 
I 15 + A 
3 
M 
0 
10 + 
5 + 
A 
A 
c 
B 
A 
c 
c 
0 + p 
Plot of MISSPI*QI26. Legend: A 
B 
c 
B 
c 
c 
A 
A 
A 
A 
A 
A 
E 
A 
A 
B 
A A 
A 
A 
A 
1 obs, B 2 obs , etc. 
---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+--
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
I DAYS IN BED/PAST 2 WKS 
NOTE: 78 obs had missing values. 
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7. Plot of #of doses missed in the past 3 months Vs #of 
hospitalization in past year 
Plot of MISSPI*QI27 . Legend: A= lobs, B 2 obs, etc. 
p 
I 
fl 
M 
I 
s 
s 
E 
D 
D 
0 
s 
E 
s 
I 
3 
M 
0 
40 + 
I 
I 
I 
I 
IA 
35 + 
30 + 
25 + 
20 + 
IA 
I 
I 
I 
IA 
15 +A 
I 
I 
I 
IA 
I 
10 + 
I 
IA 
IA 
I 
I 
5 + 
IA 
IF 
IB 
JG 
IF 
0 +P 
A 
A 
A A B A 
A A 
A 
D c c A 
-+-------+-------+-------+-------+-------+-------+-------+-------+-
0 1 2 3 4 5 6 7 8 
I HOSPITALIZATIONS/PAST YR 
NOTE: 79 obs had missing values. 
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8. Plot of # of doses missed in the past 3 months Vs Tcell count 
last tested 
Plot of MISSPI*QI31. Legend: A 
40 + 
35 + 
30 + 
p 
I 
# 
M 25 + 
I 
s 
s 
E 
D 
20 + 
D 
0 
s 
E 
s 
I 15 + 
3 
M 
0 
10 + 
I 
I 
I 
I 
I 
5 + 
A 
B 
A 
0 + 
A 
A 
A 
A 
A 
A 
A 
c 
c 
c 
H 
1 obs, B 2 obs, etc. 
· .. 
A 
B 
A 
E 
D 
J 
A 
A 
A 
B 
A 
A 
F 
---+----------------+----------------+----------------+--
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NOTE: 81 obs had missing values. 
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9. Plot of # of doses missed in the past 3 months Vs general 
mental health 
Plot of MISSPI*TGMH. Legend: A l obs, B 2 obs, etc. 
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NOTE: 81 obs had missing values. 
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10.Plot of # of doses missed in the past 3 months Vs vitality 
energy and fatigue 
Plot of MISSPI*TFAT. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 81 obs had missing values. 
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11. P1ot of # of doses missed in the past 3 months Vs seek and use 
socia1 support 
Plot of MISSPI*SSSS. Legend: A 1 obs, B 2 obs, etc. 
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NOTE: 80 obs had missing values. 
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12.Plot of doses missed in the past 3 months Vs Behavioral Escape 
Avoidance 
Plot of MISSPI*SBEA. Le ge nd: A 1 obs, B 2 obs, etc. 
40 + 
A 
35 + 
30 + 
p 
I 
# 
•' 
M 25 + 
I 
s 
s 
E A 
D 
20 + 
D A 
0 
s 
E 
s A 
I 15 + A 
3 
M 
0 A 
10 + 
A 
A 
A 
5 + 
A A A AA A 
A A A A A A 
A A 
A A c A A B 
A B A A A A 
0 + A A A A C AB A D B B B AB A A -· 
--+--------+--------+--------+--------+--------+--------+--------+-
5 10 15 20 25 30 35 40 
SBEA 
NOTE: 80 obs had missing values. 
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13. Plot of # of doses missed in the past 3 months Vs Cognitive 
Escape Avoidance 
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14. Plot of # of doses missed in the past 3 months Vs Focus on 
Positive 
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Plot of MISSPI*SFOP. Legend: A = 1 obs, B 2 obs, etc. 
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---+------------+------------+------------+------------+--
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NOTE: 80 obs had missing values. 
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( 15. Plot of # of doses missed in the past 3 months Vs. Distancing 
Plot of MISSPI*SDIS . Legend: A= 1 obs, B = 2 obs, etc. 
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---+---------+---------+---------+---------+---------+---------+--
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NOTE: 78 obs had missing values. 
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16. Plot of Temptation to skip Protease Inhibitors for the Total scale Vs General mental 
( Health 
Plot of Y*TGMH. Legend: A 1 obs, B 2 obs, etc. 
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--+---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+--
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 
TGMH 
NOTE: 78 obs had missing values . 
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( 17. Plot of Temptation to skip Protease Xnhibitors for the Total scale Vs Vitality,fatigue & energy 
Plot of Y*TE'AT. Legend: A 1 obs, B 2 obs, etc . 
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--+----+----+----+----+----+----+----+----+----+----+----+----+----+-
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TE'AT 
NOTE: 78 obs had missing values. 
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18. Plot of Temptation to skip Protease Inhibitors for the Total scale Vs Seek and use 
Social support 
Plot of Y*SSSS . Le ge nd: A l obs , B 2 obs, etc. 
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--+------------+------------+---- --------+------------+------------+-
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NOTE: 77 obs had missing values. 
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19. Plot of Temptation to skip Protease Xnhibitor for Total scale Vs Behavioral Escape 
Avoidance 
Plot of Y*SBEA. Legend: A = 1 obs, B = 2 obs, etc. 
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---+--------+--- - - -- - +- - ------+--------+--------+--------+------ --+--
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NOTE: 77 obs had missing values. 
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20. P1ot of Temptation to skip Protease Inhibitor for Total sca1e Vs Cognitive Escape 
Avoidance 
Plot of Y*SCEA. Legend: A 1 obs, B 2 obs, etc. 
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--+------------+------------+------------+------------+------------+-
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NOTE: 76 obs had missing values. 
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( 21. P1ot of Temptation to skip Protease Inhibitor for Tota1 scale Vs Focus on Positive 
Plot of Y*SFOP. Legend: A = 1 obs, B = 2 obs, etc. 
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---+------------+------------+------------+------------+--
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NOTE: 77 obs had missing values. 
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22 . Plot of Temptation to skip Protease Inhibitor for Total scale Vs Distancing 
Plot of Y*SDIS. Legend: A = 1 obs, B = 2 obs, etc. 
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-+----------+----------+----------+----------+----------+----------+-
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NOTE: 76 obs had missing values. 
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( 23. P1ot of Temptation to skip Protease Inhibitors for Tota1 Sca1e Vs Age 
Plot of Y*Qil. Legend: A = 1 obs, B = 2 obs, etc. 
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---+------------+------ ------+------------+------------+--
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AGE 
NOTE: 76 obs had missing values. 
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24. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs gender 
Plot of Y*QI2A. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 76 obs had missing values. 
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25. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs Current Health 
Status 
Plot of Y*QI3. Legend: A 
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---+------------+------------+------------+------------+--
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CURRENT HLTH STATUS 
NOTE: 76 obs had missing values. 
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26. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs Race 
Plot of Y*QI4. Legend: A= 1 obs, B = 2 obs, etc. 
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1 2 3 4 5 6 
NOTE: 77 obs had missing values. 
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27. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs Years of Education 
Plot of Y*QI5. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 77 obs had missing values . 
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( 28. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs Number of people in 
household 
Plot of Y*QI8A. 
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NOTE: 83 obs had missing values. 
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29. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs Insurance 
Plot of y•x. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 76 obs had missing values. 
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( 30. Plot of Temptation to skip Protease Inhibitors for Total Scale Vs Income 
Plot of Y*QI19. Legend: A = 1 obs, B = 2 obs, etc. 
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---+------------+------------+------------+------------+--
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ANNUAL INCOME 
NOTE: 78 obs had missing values. 
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( 31. Plot of number of doses missed in the past 3 months Vs age 
Plot of MISSPI*Qil. Legend: A - l obs, B = 2 obs, etc. 
40 + 
A 
35 + 
30 + 
p 
I 
* 
~· M 25 + 
I 
s 
s 
E A 
D 
20 + 
D A 
0 
s 
E 
s A 
I 15 + A 
3 
/ M ~_,.,. 0 A 
10 + 
A 
A 
A 
5 + A 
AA A A A A 
BA A A A 
A A 
AA A B A B A 
A A A AA A A 
0 + AA A B A ABA A.AB B B DA A A B 
---+------------+------------+------------+------------+--
20 30 40 50 60 
AGE 
NOTE: 78 obs had missing values. 
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32. Plot of number of doses missed in the past 3 months Vs Gender 
Plot of MISSPI*QI2A. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 78 obs had missing values. 
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33. Plot of number of doses missed in the past 3 months Vs Current health status 
Plot of MISSPI*QI3. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 78 obs had missing values. 
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34. Plot of number of doses missed in the past 3 months Vs Race 
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Plot of MISSPI*QI4. Legend: A= 1 obs, B = 2 obs, etc. 
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35. Plot of number of doses missed in the past 3 months Vs Years of Education 
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Plot o f MISSPI *QI5. Legend : A = 1 obs, B = 2 obs, etc. 
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NOTE: 79 obs had missing values. 
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36. Plot of number of doses missed in the past 3 months Vs number of people in household 
Plot of MISSPI *QIBA. Legend : A 1 o b s , B = 2 obs, etc. 
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NOTE: 84 obs had missing values. 
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37. P1ot of number of doses missed in the past 3 months vs Income 
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NOTE: 79 obs had missing values. 
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38 . Plot of number of doses missed in the past 3 months Vs Insurance 
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Plot of MISSPI*X. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 78 obs had missing values. 
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1. Plot of pain interfering with work in the past 4 weeks Vs 
Temptation to skip Pro tease Inhibitors for total scale 
Frequency 
**** 
**** 
30 + **** 
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**** **** **** 
**** **** **** 
**** **** **** 
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I **** **** **** 
I **** **** **** 
I **** **** **** 
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I **** **** **** **** **** **** **** **** **** 
I **** **** **** **** **** **** **** **** **** **** 
---------------------------------------------------------------
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2. Plot of# of days in bed in the past 2 weeks Vs Temptation to skip Protease Inhibitors 
for total scale 
Frequency 
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3. Plot of# of hospitalization in the past year Vs Temptation to skip Protease Inhibitors 
for total scale 
Frequency 
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***** ***** ***** ***** ***** 
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4. Plot of T cell count last tested Vs Temptation to skip Protease Inhibitors for total scale 
Frequency 
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5. Plot of pain interfering with work in the past 4 weeks Vs # of doses missed in the past 
three months 
Frequency 
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6. Plot of# of days in bed in the past 2 weeks Vs # of doses missed in the past 3 months 
Frequency 
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7. Plot of# of hospitalization in the past year Vs # of doses missed in the past three 
months 
Frequency 
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8. Plot ofT cell count last tested Vs# of doses missed in the past three months 
Frequency 
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9. Plot of General mental health Vs# of doses missed in the past three months 
Frequency 
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l 0. Plot of vitality energy and fatigue Vs # of doses missed in the past three months 
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11 . Plot of seek and use social support Vs # of doses missed in the past three months 
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12. Plot of Behavioral escape avoidance Vs# of doses missed in the past 3 months 
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13 . Plot of cognitive escape avoidance Vs # of doses missed in the past 3 months 
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14. Plot of focus on positive Vs # of doses missed in the past three months 
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15 . Plot of Distancing Vs # of doses missed in the past 3 months 
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t 6. Plot of General mental Health Vs Temptation to skip Protease inhibitors for total scale 
fre que n cy 
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17. Plot of Vitality energy and fatigue Vs Temptation to skip Protease inhibitors for total 
scale 
Frequency 
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( 18. Plot of seek and use social support Vs Temptation to skip Protease inhibitors for total 
scale 
Frequency 
330 + 
I 
I 
I 
300 + 
270 + 
I 
I 
I 
240 + 
210 + 
I 
I 
I 
180 + 
I 
I 
I 
150 + 
120 + 
I 
I 
I 
90 + 
I 
I 
I 
60 + 
I 
I 
I 
30 + 
I 
I 
I 
** 
** 
** 
** 
1 
2 
7 
5 
1 
4 
2 
5 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
* * 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** ** ** 
** ** ** 
** ** ** 
** 
** 
** 
** 
** 
** 
** 
'** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** ** ** ** ** 
** ** ** ** ** ** 
** ** ** ** ** ** 
** ** ** ** ** ** ** 
** 
** 
** 
** 
** 
** 
** 
** 
** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** ** ** ** 
** ** ** ** ** ** ** ** ** ** ** 
** 
** 
** 
** 
1 
5 
7 
5 
** 
** 
** 
** 
1 
7 
2 
5 
** 
** 
** 
** 
1 
8 
7 
5 
** 
** 
** 
** 
2 
0 
2 
5 
** 
** 
** 
** 
2 
1 
7 
5 
** 
** 
** 
** 
2 
3 
2 
5 
** 
** 
** 
** 
2 
4 
7 
5 
** 
** 
** 
** 
2 
6 
2 
5 
** 
** 
** 
** 
2 
7 
7 
5 
Y Midpoint 
155 
** 
** 
** 
** 
2 
9 
2 
5 
** 
** 
** 
** 
3 '3 
0 2 
7 2 
5 5 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** ** 
** ** 
** ** ** 
** ** ** ** 
** ** ** ** ** 
** 
** 
** 
** 
3 
3 
7 
5 
** 
** 
** 
** 
3 
5 
2 
5 
** 
** 
** 
** 
3 
6 
7 
5 
** 
** 
** 
** 
3 
8 
2 
5 
** 
** 
** 
** 
3 
9 
7 
5 
( 
, 
/ . 
_ _ ,,,,.. ,,. 
,,-·-
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21. Plot of Focus on Positive Vs Temptation to skip Protease Inhibitors for total scale 
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24. Plot of current health status Vs temptation to skip Protease Inhibitors for total scale 
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25. Plot of race Vs Temptation to skip Protease Inhibitors for total scale 
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( 26. Years of education Vs Temptation to skip Protease Inhibitors for total scale 
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27. Number of people in household Vs Temptation to skip Protease Inhibitors for total 
scale 
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28. Insurance Vs Temptation to skip Protease Inhibitors for total scale 
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32. Race Vs# of doses missed in the past three months 
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( 3 3. Years of education Vs # of doses missed in the past three months 
Frequency 
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{ 34. #of people in household Vs# of doses missed in the past three months 
Frequency 
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36. Income Vs# of doses of missed in the past three months 
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